SB 1089: Preventive Treatment Health Care Act.
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2026-09-28
Current Status:
Passed
(2026-09-28: Chaptered by Secretary of State. Chapter 725, Statutes of 2026.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law additionally authorizes CHHSA to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns.
This bill, the Preventive Treatment Health Care Act, would authorize CHHSA to enter into partnerships, if needed and subject to an appropriation, to increase competition, lower prices, and address supply shortages for at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration (FDA). The bill would require CHHSA to establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law additionally authorizes CHHSA to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns.
This bill, the Preventive Treatment Health Care Act, would authorize CHHSA to enter into partnerships, if needed and subject to an appropriation, to increase competition, lower prices, and address supply shortages for at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration (FDA). The bill would require CHHSA to establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law additionally authorizes CHHSA to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns.
This bill, the Preventive Treatment Health Care Act, would specify that the above-described authorized partnerships include those authorize CHHSA to enter into partnerships, if needed and subject to an appropriation, to increase competition, lower prices, and address supply shortages for at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration (FDA). The bill would require CHHSA to establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law additionally authorizes CHHSA to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns.
This bill, the Preventive Treatment Health Care Act, would specify that the above-described authorized partnerships include those for at least one glucagon-like peptide-1 (GLP-1) approved by the United States Food and Drug Administration (FDA).
(2)Existing law authorizes the Board of Administration of the Public Employees Retirement System to contract with carriers to provide health benefit plans and contracts for employees and annuitants. Existing law sets forth specified coverage requirements for these health benefit plans and contracts.Commencing January 1, 2028, until January 1, 2032, this bill would require a health benefit plan or contract offered to public employees and annuitants to offer coverage for chronic weight disease management or to treat obesity or overweight persons, including nutritional information and at least one GLP-1 approved by the FDA.(1)Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law additionally authorizes CHHSA to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns.
This bill, the Preventive Treatment Health Care Act, would specify that the above-described authorized partnerships include those for at least one glucagon-like peptide-1 (GLP-1) approved by the United States Food and Drug Administration (FDA).
(2)Existing law authorizes the Board of Administration of the Public Employees Retirement System to contract with carriers to provide health benefit plans and contracts for employees and annuitants. Existing law sets forth specified coverage requirements for these health benefit plans and contracts.
Commencing January 1, 2028, until January 1, 2032, this bill would require a health benefit plan or contract offered to public employees and annuitants to offer coverage for chronic weight disease management, management or to treat obesity or overweight persons, including nutritional information and at least one GLP-1 approved by the FDA.
(1)Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law requires the insulin production partnership to consider guaranteeing priority access to insulin supply for the state. additionally authorizes CHHSA to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns.
This bill, the Preventive Treatment Health Care Act, would require the above-described partnerships to also include the acquisition of brand name prescription drugs and the acquisition or production of pens, vial injections, pills, and patches of specify that the above-described authorized partnerships include those for at least one glucagon-like peptide-1 (GLP-1) semaglutide, GLP-1 receptor agonist (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products made available at production and dispensing costs and to consider guaranteeing priority access to GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products supply for the state. approved by the United States Food and Drug Administration (FDA).
(2)Existing law authorizes the Board of Administration of the Public Employees Retirement System to contract with carriers to provide health benefit plans and contracts for employees and annuitants. Existing law sets forth specified coverage requirements for these health benefit plans and contracts.
Commencing January 1, 2027, 2028, until January 1, 2032, this bill would require a health benefit plan or contract offered to public employees and annuitants to offer optional coverage for weight loss chronic weight disease management, including nutritional information and GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products as part of one of its health plan options. The bill would specify cost and usage requirements for these covered chronic weight disease management items. The bill would require CHHSA to make chronic weight disease management medications available to state and local government employers, and to determine if chronic weight disease management medications should be made available to all Californians, at the costs for which they are available under a Public Employees Retirement System health benefit plan or contract. at least one GLP-1 approved by the FDA.
(1)Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law requires the insulin production partnership to consider guaranteeing priority access to insulin supply for the state.
This bill, the Preventive Treatment Health Care Act, would require the above-described partnerships to also include the production of at least one acquisition of brand name prescription drugs and the acquisition or production of pens, vial injections, pills, and patches of glucagon-like peptide-1 (GLP-1) or semaglutide, GLP-1 receptor agonist (GLP-1RA) (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products made available at production and dispensing costs and to consider guaranteeing priority access to GLP-1 or GLP-1RA semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products supply for the state.
(2)Existing law requires the State Department of Health Care Services to negotiate drug discount agreements with drug manufacturers and to encourage manufacturers to maintain private discount drug programs.This bill would authorize an employer with 100 or more employees to negotiate directly with a drug manufacturer to provide a discount for a GLP-1 or GLP-1RA.(3)Existing law sets forth the obligations of an employer in the employment relationship with an employee.This bill would require an employer with 100 or more to offer its employees access to exercise programs, gym memberships, or both, nutrition programs, and coverage for a GLP-1 or GLP-1RA.(4)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for plan contracts and insurance policies.This bill would require a large group health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, to cover weight loss as a medical condition. The bill would require a health care service plan contract that provides coverage for outpatient prescription drug benefits and is issued, amended, or renewed on or after January 1, 2027, to include coverage for at least one antiobesity medication approved by the United States Food and Drug Administration. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.(5)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.This bill would provide that no reimbursement is required by this act for a specified reason.(2)Existing law authorizes the Board of Administration of the Public Employees Retirement System to contract with carriers to provide health benefit plans and contracts for employees and annuitants. Existing law sets forth specified coverage requirements for these health benefit plans and contracts.
Commencing January 1, 2027, until January 1, 2032, this bill would require a health benefit plan or contract offered to public employees and annuitants to offer optional coverage for weight loss management, including nutritional information and GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products as part of one of its health plan options. The bill would specify cost and usage requirements for these covered chronic weight disease management items. The bill would require CHHSA to make chronic weight disease management medications available to state and local government employers, and to determine if chronic weight disease management medications should be made available to all Californians, at the costs for which they are available under a Public Employees Retirement System health benefit plan or contract.
(1)Existing law requires the California Health and Human Services Agency to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law requires the insulin production partnership to consider guaranteeing priority access to insulin supply for the state.
This bill, the Preventive Care Act, would require the above-described partnerships to also include the production of at least one glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist (GLP-1RA) made available at production and dispensing costs and to consider guaranteeing priority access to GLP-1 or GLP-1RA supply for the state.
(2)Existing law requires the State Department of Health Care Services to negotiate drug discount agreements with drug manufacturers and to encourage manufacturers to maintain private discount drug programs.
This bill would authorize an employer with 100 or more employees to negotiate directly with a drug manufacturer to provide a discount for a GLP-1 or GLP-1RA.
(3)Existing law sets forth the obligations of an employer in the employment relationship with an employee.
This bill would require an employer with 100 or more to offer its employees access to exercise programs, gym memberships, or both, nutrition programs, and coverage for a GLP-1 or GLP-1RA.
(4)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for plan contracts and insurance policies.
This bill would require a large group health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, to cover weight loss as a medical condition. The bill would require a health care service plan contract that provides coverage for outpatient prescription drug benefits and is issued, amended, or renewed on or after January 1, 2027, to include coverage for at least one antiobesity medication approved by the United States Food and Drug Administration. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
(5)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
This act shall be known, and may be cited, as the Preventive Treatment Health Care Act.
SEC. 2.The Legislature finds and declares all of the following:
(a)There are approximately 30,000,000 adults 18 years of age and older living in California.
(b)(1)According to the University of California, Los Angeles, California Health Interview Survey, nearly 61 percent of, or more than 24,500,000, California adults 18 to 64 years of age, inclusive, are suffering from chronic weight disease, thereby falling into the combined overweight or obese category.
(2)The body mass index (BMI) is a formula that screens for excess weight relative to height.
(3)The federal Centers for Disease Control and Prevention classifies weight into six categories. The BMI formula used is categorized as follows:
| Underweight | BMI below 18.5 |
| Healthy weight | BMI 18.5 to 24.9 |
| Overweight | BMI 25.0 to 29.9 |
| Class 1 Obesity | BMI 30.0 to 34.9 |
| Class 2 Obesity | BMI 35.0 to 39.9 |
| Class 3 Obesity | BMI 40.0 and above |
(4)Further, BMI is measured to determine risk for weight-related disease often associated with a waist size of 35 inches or more in women and 40 inches or more in men.
(c)Californians with a greater determination of overweight beyond a BMI higher than 30.0 are clinically described as obese, which has increased from 19.3 percent in 2001 to over 29 percent in 2023. Even more alarming, without prevention, obesity could reach 41 percent by 2030 in California adults.
(d)Serious chronic weight disease with a BMI formula rating over 30 is recognized as such by major medical organizations, including the American Medical Association since 2013, the American Association of Clinical Endocrinology, the American College of Cardiology, the Endocrine Society, the American Society for Reproductive Medicine, the Society for Cardiovascular Angiography and Interventions, the American Urological Association, and the American College of Surgeons.
(e)(1)Chronic weight disease extends beyond the need to lose pounds but can also contribute to possible cancers and other comorbidities. From 2005 to 2014, several cancers that may be associated with chronic weight disease have increased in the United States, while cancers associated with other health factors decreased.
(2)Chronic weight disease reduces a patients overall cancer-specific survival rate, as well as increases the risk of cancer recurrence.
(3)The 13 types of cancer related to chronic weight disease are:
(A)Adenocarcinoma of the esophagus.
(B)Postmenopausal breast.
(C)Colon and rectal, or colorectal.
(D)Endometrial of the uterus.
(E)Gallbladder.
(F)Gastric cardia, or upper stomach.
(G)Renal cell carcinoma of the kidney.
(H)Liver.
(I)Ovarian.
(J)Pancreatic.
(K)Thyroid.
(L)Meningioma, a type of brain cancer.
(M)Multiple myeloma, a blood cancer.
(4)Chronic weight disease is associated with an increased risk of more than 200 comorbid conditions. Some of those conditions are:
(A)Type 2 diabetes.
(B)High blood pressure.
(C)Heart disease.
(D)Stroke.
(E)Metabolic syndrome.
(F)Fatty liver diseases.
(G)Other types of cancers.
(H)Breathing problems.
(I)Osteoarthritis.
(J)Gout.
(K)Diseases of the gallbladder and pancreas.
(L)Kidney disease.
(M)Pregnancy problems.
(N)Fertility problems.
(O)Sexual function problems.
(P)Mental health problems.
(f)(1)In addition to individual health impacts of chronic weight disease, employee productivity and contributions to Californias economy are impacted by the prevention and management of chronic weight disease.
(2)Chronic weight disease can be related to reduced labor participation and earnings and increased early mortality, absenteeism, disability, and health care costs exceeding $1 billion and a 2.6-percent reduction in the California gross domestic product.
(g)Barriers to the reduction, maintenance, or elimination of chronic weight disease are essentially access and cost.
(h)This act is intended to promote access to affordable glucagon-like peptide-1 (GLP-1) weight management medication for Californians, which includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medications in this category.
SEC. 3.Section 127697 of the Health and Safety Code is amended to read:127697.(a)In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships to increase competition, lower prices, and address supply shortages under any of the following circumstances:
(1)For over-the-counter naloxone products. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of over-the-counter naloxone products by an entity that is authorized to do so under federal or state law.
(2)For generic or brand name drugs to address emerging health concerns, including in reproductive health care and gender-affirming health care.
(3)For the development, production, procurement, or distribution of vaccines, by an entity that is authorized to do so under federal or state law, with the intent that these vaccines be made widely available to public and private purchasers, providers, suppliers, and pharmacies.
(4)For the manufacture, purchase, or distribution of medical supplies or medical devices.
(b)In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships, if needed, to increase competition, lower prices, and address supply shortages for at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration. For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medications in this category. The California Health and Human Services Agency shall also establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
This act shall be known, and may be cited, as the Preventive Treatment Health Care Act.
SEC. 2.The Legislature finds and declares all of the following:
(a)There are approximately 30,000,000 adults 18 years of age and older living in California.
(b)(1)According to the University of California, Los Angeles, California Health Interview Survey, nearly 61 percent of, or more than 24,500,000, California adults 18 to 64 years of age, inclusive, are suffering from chronic weight disease, thereby falling into the combined overweight or obese category.
(2)The body mass index (BMI) is a formula that screens for excess weight relative to height.
(3)The federal Centers for Disease Control and Prevention classifies weight into six categories. The BMI formula used is categorized as follows:
| Underweight | BMI below 18.5 |
| Healthy weight | BMI 18.5 to 24.9 |
| Overweight | BMI 25.0 to 29.9 |
| Class 1 Obesity | BMI 30.0 to 34.9 |
| Class 2 Obesity | BMI 35.0 to 39.9 |
| Class 3 Obesity | BMI 40.0 and above |
(4)Further, BMI is measured to determine risk for weight-related disease often associated with a waist size of 35 inches or more in women and 40 inches or more in men.
(c)Californians with a greater determination of overweight beyond a BMI higher than 30.0 are clinically described as obese, which has increased from 19.3 percent in 2001 to over 29 percent in 2023. Even more alarming, without prevention, obesity could reach 41 percent by 2030 in California adults.
(d)Serious chronic weight disease with a BMI formula rating over 30 is recognized as such by major medical organizations, including the American Medical Association since 2013, the American Association of Clinical Endocrinology, the American College of Cardiology, the Endocrine Society, the American Society for Reproductive Medicine, the Society for Cardiovascular Angiography and Interventions, the American Urological Association, and the American College of Surgeons.
(e)(1)Chronic weight disease extends beyond the need to lose pounds but can also contribute to possible cancers and other comorbidities. From 2005 to 2014, several cancers that may be associated with chronic weight disease have increased in the United States, while cancers associated with other health factors decreased.
(2)Chronic weight disease reduces a patients overall cancer-specific survival rate, as well as increases the risk of cancer recurrence.
(3)The 13 types of cancer related to chronic weight disease are:
(A)Adenocarcinoma of the esophagus.
(B)Postmenopausal breast.
(C)Colon and rectal, or colorectal.
(D)Endometrial of the uterus.
(E)Gallbladder.
(F)Gastric cardia, or upper stomach.
(G)Renal cell carcinoma of the kidney.
(H)Liver.
(I)Ovarian.
(J)Pancreatic.
(K)Thyroid.
(L)Meningioma, a type of brain cancer.
(M)Multiple myeloma, a blood cancer.
(4)Chronic weight disease is associated with an increased risk of more than 200 comorbid conditions. Some of those conditions are:
(A)Type 2 diabetes.
(B)High blood pressure.
(C)Heart disease.
(D)Stroke.
(E)Metabolic syndrome.
(F)Fatty liver diseases.
(G)Other types of cancers.
(H)Breathing problems.
(I)Osteoarthritis.
(J)Gout.
(K)Diseases of the gallbladder and pancreas.
(L)Kidney disease.
(M)Pregnancy problems.
(N)Fertility problems.
(O)Sexual function problems.
(P)Mental health problems.
(f)(1)In addition to individual health impacts of chronic weight disease, employee productivity and contributions to Californias economy are impacted by the prevention and management of chronic weight disease.
(2)Chronic weight disease can be related to reduced labor participation and earnings and increased early mortality, absenteeism, disability, and health care costs exceeding $1 billion and a 2.6-percent reduction in the California gross domestic product.
(g)Barriers to the reduction, maintenance, or elimination of chronic weight disease are essentially access and cost.
(h)This act is intended to promote access to affordable glucagon-like peptide-1 (GLP-1) weight management medication for Californians, which includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medications in this category.
SEC. 3.Section 127697 of the Health and Safety Code is amended to read:127697.(a)In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships to increase competition, lower prices, and address supply shortages under any of the following circumstances:
(1)For over-the-counter naloxone products. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of over-the-counter naloxone products by an entity that is authorized to do so under federal or state law.
(2)For generic or brand name drugs to address emerging health concerns, including in reproductive health care and gender-affirming health care.
(3)For the development, production, procurement, or distribution of vaccines, by an entity that is authorized to do so under federal or state law, with the intent that these vaccines be made widely available to public and private purchasers, providers, suppliers, and pharmacies.
(4)For the manufacture, purchase, or distribution of medical supplies or medical devices.
(b)In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships, if needed, to increase competition, lower prices, and address supply shortages for at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration. For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medications in this category. The California Health and Human Services Agency shall also establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
This act shall be known, and may be cited, as the Preventive Treatment Health Care Act.
SEC. 2.The Legislature finds and declares all of the following:
(a)There are approximately 30,000,000 adults 18 years of age and older living in California.
(b)(1)According to the University of California, Los Angeles, California Health Interview Survey, nearly 61 percent of, or more than 24,500,000, California adults 18 to 64 years of age, inclusive, are suffering from chronic weight disease, thereby falling into the combined overweight or obese category.
(2)The body mass index (BMI) is a formula that screens for excess weight relative to height.
(3)The federal Centers for Disease Control and Prevention classifies weight into six categories. The BMI formula used is categorized as follows:
| Underweight | BMI below 18.5 |
| Healthy weight | BMI 18.5 to 24.9 |
| Overweight | BMI 25.0 to 29.9 |
| Class 1 Obesity | BMI 30.0 to 34.9 |
| Class 2 Obesity | BMI 35.0 to 39.9 |
| Class 3 Obesity | BMI 40.0 and above |
(4)Further, BMI is measured to determine risk for weight-related disease often associated with a waist size of 35 inches or more in women and 40 inches or more in men.
(c)Californians with a greater determination of overweight beyond a BMI higher than 30.0 are clinically described as obese, which has increased from 19.3 percent in 2001 to over 29 percent in 2023. Even more alarming, without prevention, obesity could reach 41 percent by 2030 in California adults.
(d)Serious chronic weight disease with a BMI formula rating over 30 is recognized as such by major medical organizations, including the American Medical Association since 2013, the American Association of Clinical Endocrinology, the American College of Cardiology, the Endocrine Society, the American Society for Reproductive Medicine, the Society for Cardiovascular Angiography and Interventions, the American Urological Association, and the American College of Surgeons.
(e)(1)Chronic weight disease extends beyond the need to lose pounds but can also contribute to possible cancers and other comorbidities. From 2005 to 2014, several cancers that may be associated with chronic weight disease have increased in the United States, while cancers associated with other health factors decreased.
(2)Chronic weight disease reduces a patients overall cancer-specific survival rate, as well as increases the risk of cancer recurrence.
(3)The 13 types of cancer related to chronic weight disease are:
(A)Adenocarcinoma of the esophagus.
(B)Postmenopausal breast.
(C)Colon and rectal, or colorectal.
(D)Endometrial of the uterus.
(E)Gallbladder.
(F)Gastric cardia, or upper stomach.
(G)Renal cell carcinoma of the kidney.
(H)Liver.
(I)Ovarian.
(J)Pancreatic.
(K)Thyroid.
(L)Meningioma, a type of brain cancer.
(M)Multiple myeloma, a blood cancer.
(4)Chronic weight disease is associated with an increased risk of more than 200 comorbid conditions. Some of those conditions are:
(A)Type 2 diabetes.
(B)High blood pressure.
(C)Heart disease.
(D)Stroke.
(E)Metabolic syndrome.
(F)Fatty liver diseases.
(G)Other types of cancers.
(H)Breathing problems.
(I)Osteoarthritis.
(J)Gout.
(K)Diseases of the gallbladder and pancreas.
(L)Kidney disease.
(M)Pregnancy problems.
(N)Fertility problems.
(O)Sexual function problems.
(P)Mental health problems.
(f)(1)In addition to individual health impacts of chronic weight disease, employee productivity and contributions to Californias economy are impacted by the prevention and management of chronic weight disease.
(2)Chronic weight disease can be related to reduced labor participation and earnings and increased early mortality, absenteeism, disability, and health care costs exceeding $1 billion and a 2.6-percent reduction in the California gross domestic product.
(g)Barriers to the reduction, maintenance, or elimination of chronic weight disease are essentially access and cost.
(h)This act is intended to promote access to affordable glucagon-like peptide-1 (GLP-1) weight management medication for Californians. Californians, which includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medications in this category.
SEC. 3.Section 127697 of the Health and Safety Code is amended to read:127697.(a)In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships to increase competition, lower prices, and address supply shortages under any of the following circumstances:
(a)(1)For over-the-counter naloxone products. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of over-the-counter naloxone products by an entity that is authorized to do so under federal or state law.
(b)(2)For generic or brand name drugs to address emerging health concerns, including in reproductive health care, gender affirming care and gender-affirming health care, or at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration. For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide. The California Health and Human Services Agency shall also make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025. care.
(c)(3)For the development, production, procurement, or distribution of vaccines, by an entity that is authorized to do so under federal or state law, with the intent that these vaccines be made widely available to public and private purchasers, providers, suppliers, and pharmacies.
(d)(4)For the manufacture, purchase, or distribution of medical supplies or medical devices.
(b)In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships, if needed, to increase competition, lower prices, and address supply shortages for at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration. For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medications in this category. The California Health and Human Services Agency shall also establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
This act shall be known, and may be cited, as the Preventive Treatment Health Care Act.
SEC. 2.The Legislature finds and declares all of the following:
(a)There are approximately 30,000,000 adults 18 years of age and older living in California.
(b)(1)According to the University of California, Los Angeles, California Health Interview Survey, nearly 61 percent of, or more than 24,500,000, California adults 18 to 64 years of age, inclusive, are suffering from chronic weight disease, thereby falling into the combined overweight or obese category.
(2)The body mass index (BMI) is a formula that screens for excess weight relative to height.
(3)The federal Centers for Disease Control and Prevention classifies weight into six categories. The BMI formula used is categorized as follows:
| Underweight | BMI below 18.5 |
| Healthy weight | BMI 18.5 to 24.9 |
| Overweight | BMI 25.0 to 29.9 |
| Class 1 Obesity | BMI 30.0 to 34.9 |
| Class 2 Obesity | BMI 35.0 to 39.9 |
| Class 3 Obesity | BMI 40.0 and above |
(4)Further, BMI is measured to determine risk for weight-related disease often associated with a waist size of 35 inches or more in women and 40 inches or more in men.
(c)Californians with a greater determination of overweight beyond a BMI higher than 30.0 are clinically described as obese, which has increased from 19.3 percent in 2001 to over 29 percent in 2023. Even more alarming, without prevention, obesity could reach 41 percent by 2030 in California adults.
(d)Serious chronic weight disease with a BMI formula rating over 30 is recognized as such by major medical organizations, including the American Medical Association since 2013, the American Association of Clinical Endocrinology, the American College of Cardiology, the Endocrine Society, the American Society for Reproductive Medicine, the Society for Cardiovascular Angiography and Interventions, the American Urological Association, and the American College of Surgeons.
(e)(1)Chronic weight disease extends beyond the need to lose pounds but can also contribute to possible cancers and other comorbidities. From 2005 to 2014, several cancers that may be associated with chronic weight disease have increased in the United States, while cancers associated with other health factors decreased.
(2)Chronic weight disease reduces a patients overall cancer-specific survival rate, as well as increases the risk of cancer recurrence.
(3)The 13 types of cancer related to chronic weight disease are:
(A)Adenocarcinoma of the esophagus.
(B)Postmenopausal breast.
(C)Colon and rectal, or colorectal.
(D)Endometrial of the uterus.
(E)Gallbladder.
(F)Gastric cardia, or upper stomach.
(G)Renal cell carcinoma of the kidney.
(H)Liver.
(I)Ovarian.
(J)Pancreatic.
(K)Thyroid.
(L)Meningioma, a type of brain cancer.
(M)Multiple myeloma, a blood cancer.
(4)Chronic weight disease is associated with an increased risk of more than 200 comorbid conditions. Some of those conditions are:
(A)Type 2 diabetes.
(B)High blood pressure.
(C)Heart disease.
(D)Stroke.
(E)Metabolic syndrome.
(F)Fatty liver diseases.
(G)Other types of cancers.
(H)Breathing problems.
(I)Osteoarthritis.
(J)Gout.
(K)Diseases of the gallbladder and pancreas.
(L)Kidney disease.
(M)Pregnancy problems.
(N)Fertility problems.
(O)Sexual function problems.
(P)Mental health problems.
(f)(1)In addition to individual health impacts of chronic weight disease, employee productivity and contributions to Californias economy are impacted by the prevention and management of chronic weight disease.
(2)Chronic weight disease can be related to reduced labor participation and earnings and increased early mortality, absenteeism, disability, and health care costs exceeding $1 billion and a 2.6-percent reduction in the California gross domestic product.
(g)Barriers to the reduction, maintenance, or elimination of chronic weight disease are essentially access and cost.
(h)This act is intended to promote access to affordable glucagon-like peptide-1 (GLP-1) weight management medication for Californians.
SEC. 3.Section 22853.5 is added to the Government Code, to read:22853.5.(a)Commencing January 1, 2028, a health benefit plan or contract that contracts with the board pursuant to this chapter shall offer coverage for chronic weight disease management or to treat obesity or overweight persons, including nutritional information and at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration.(b)When determining the cost for weight disease management or treatments for obesity or overweight persons covered pursuant to subdivision (a), the cost to Medi-Cal beneficiaries in the year 2025 or better pricing may be considered.(c)Chronic weight disease management or treatments for obesity or overweight persons covered pursuant to subdivision (a) shall follow the indications for use in the label approved by the United States Food and Drug Administration.(d)For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide.(e)This section shall remain in effect only until January 1, 2032, and as of that date is repealed.SEC. 4.SEC. 3.Section 127697 of the Health and Safety Code is amended to read:127697.In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships to increase competition, lower prices, and address supply shortages under any of the following circumstances:
(a)For over-the-counter naloxone products. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of over-the-counter naloxone products by an entity that is authorized to do so under federal or state law.
(b)For generic or brand name drugs to address emerging health concerns, including in reproductive health care, gender affirming health care, or at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration. For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide. The California Health and Human Services Agency shall also make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
(c)For the development, production, procurement, or distribution of vaccines, by an entity that is authorized to do so under federal or state law, with the intent that these vaccines be made widely available to public and private purchasers, providers, suppliers, and pharmacies.
(d)For the manufacture, purchase, or distribution of medical supplies or medical devices.
This act shall be known, and may be cited, as the Preventive Treatment Health Care Act.
SEC. 2.The Legislature finds and declares all of the following:
(a)There are approximately 30,000,000 adults 18 years of age and older living in California.
(b)(1)According to the University of California, Los Angeles, California Health Interview Survey, nearly 61 percent of, or more than 24,500,000, California adults 18 to 64 years of age, inclusive, are suffering from chronic weight disease, thereby falling into the combined overweight or obese category.
(2)The body mass index (BMI) is a formula that screens for excess weight relative to height.
(3)The federal Centers for Disease Control and Prevention classifies weight into six categories. The BMI formula used is categorized as follows:
| Underweight | BMI below 18.5 |
| Healthy weight | BMI 18.5 to 24.9 |
| Overweight | BMI 25.0 to 29.9 |
| Class 1 Obesity | BMI 30.0 to 34.9 |
| Class 2 Obesity | BMI 35.0 to 39.9 |
| Class 3 Obesity | BMI 40.0 and above |
(4)Further, BMI is measured to determine risk for weight-related disease often associated with a waist size of 35 inches or more in women and 40 inches or more in men.
(c)Californians with a greater determination of overweight beyond a BMI higher than 30.0 are clinically described as obese, which has increased from 19.3 percent in 2001 to over 29 percent in 2023. Even more alarming, without prevention, obesity could reach 41 percent by 2030 in California adults.
(d)Serious chronic weight disease with a BMI formula rating over 30 is recognized as such by major medical organizations, including the American Medical Association since 2013, the American Association of Clinical Endocrinology, the American College of Cardiology, the Endocrine Society, the American Society for Reproductive Medicine, the Society for Cardiovascular Angiography and Interventions, the American Urological Association, and the American College of Surgeons.
(e)(1)Chronic weight disease extends beyond the need to lose pounds but can also contribute to possible cancers and other comorbidities. From 2005 to 2014, several cancers that may be associated with chronic weight disease have increased in the United States, while cancers associated with other health factors decreased.
(2)Chronic weight disease reduces a patients overall cancer-specific survival rate, as well as increases the risk of cancer recurrence.
(3)The 13 types of cancer related to chronic weight disease are:
(A)Adenocarcinoma of the esophagus.
(B)Postmenopausal breast.
(C)Colon and rectal, or colorectal.
(D)Endometrial of the uterus.
(E)Gallbladder.
(F)Gastric cardia, or upper stomach.
(G)Renal cell carcinoma of the kidney.
(H)Liver.
(I)Ovarian.
(J)Pancreatic.
(K)Thyroid.
(L)Meningioma, a type of brain cancer.
(M)Multiple myeloma, a blood cancer.
(4)Chronic weight disease is associated with an increased risk of more than 200 comorbid conditions. Some of those conditions are:
(A)Type 2 diabetes.
(B)High blood pressure.
(C)Heart disease.
(D)Stroke.
(E)Metabolic syndrome.
(F)Fatty liver diseases.
(G)Other types of cancers.
(H)Breathing problems.
(I)Osteoarthritis.
(J)Gout.
(K)Diseases of the gallbladder and pancreas.
(L)Kidney disease.
(M)Pregnancy problems.
(N)Fertility problems.
(O)Sexual function problems.
(P)Mental health problems.
(f)(1)In addition to individual health impacts of chronic weight disease, employee productivity and contributions to Californias economy are impacted by the prevention and management of chronic weight disease.
(2)Chronic weight disease can be related to reduced labor participation and earnings and increased early mortality, absenteeism, disability, and health care costs exceeding $1 billion and a 2.6-percent reduction in the California gross domestic product.
(g)Barriers to the reduction, maintenance, or elimination of chronic weight disease are essentially access and cost.
(h)This act is intended to promote access to affordable glucagon-like peptide-1 (GLP-1) weight management medication for Californians.
SEC. 3.Section 22853.5 is added to the Government Code, to read:22853.5.(a)Commencing January 1, 2028, a health benefit plan or contract that contracts with the board pursuant to this chapter shall offer coverage for chronic weight disease management, management or to treat obesity or overweight persons, including nutritional information and at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration.
(b)Chronic(b)When determining the cost for weight disease management or treatments for obesity or overweight persons covered pursuant to subdivision (a) shall be offered at the cost previously provided (a), the cost to Medi-Cal beneficiaries in the year 2025 or the most favored nation pricing, as set forth in federal Executive Order No. 14297 on May 12, 2025, or better pricing. pricing may be considered.
(c)Chronic weight disease management or treatments for obesity or overweight persons covered pursuant to subdivision (a) shall follow the indications for use in the label approved by the United States Food and Drug Administration label indications for usage. Administration.
(d)For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide.
(e)This section shall remain in effect only until January 1, 2032, and as of that date is repealed.
SEC. 4.Section 127697 of the Health and Safety Code is amended to read:127697.In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships to increase competition, lower prices, and address supply shortages under any of the following circumstances:
(a)For over-the-counter naloxone products. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of over-the-counter naloxone products by an entity that is authorized to do so under federal or state law.
(b)For generic or brand name drugs to address emerging health concerns, including in reproductive health care, gender affirming health care, or at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration. For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide. The California Health and Human Services Agency shall also make its best effort to negotiate pricing at or lower than the most favored nation or Medi-Cal. cost to Medi-Cal beneficiaries in 2025.
(c)For the development, production, procurement, or distribution of vaccines, by an entity that is authorized to do so under federal or state law, with the intent that these vaccines be made widely available to public and private purchasers, providers, suppliers, and pharmacies.
(d)For the manufacture, purchase, or distribution of medical supplies or medical devices.
This act shall be known, and may be cited, as the Preventive Treatment Health Care Act.
SEC. 2.The Legislature finds and declares all of the following:
(a)There are approximately 30,000,000 adults 18 years of age and older living in California.
(b)(1)According to the University of California, Los Angeles, California Health Interview Survey, nearly 61 percent of, or more than 24,500,000, California adults 18 to 64 years of age, inclusive, are suffering from chronic weight disease, thereby falling into the combined overweight or obese category.
(2)The body mass index (BMI) is a formula that screens for excess weight relative to height.
(3)The federal Centers for Disease Control and Prevention classifies weight into six categories. The BMI formula used is categorized as follows:
| Underweight | BMI below 18.5 |
| Healthy weight | BMI 18.5 to 24.9 |
| Overweight | BMI 25.0 to 29.9 |
| Class 1 Obesity | BMI 30.0-34.9 30.0 to 34.9 |
| Class 2 Obesity | BMI 35.0 to 39.9 |
| Class 3 Obesity | BMI 40.0 and above |
(4)Further, BMI is measured to determine risk for weight-related disease often associated with a waist size of 35 inches or more in women and 40 inches or more in men.
(c)Californians with a greater determination of overweight beyond a BMI higher than 30.0 are clinically described as obese, which has increased from 19.3 percent in 2001 to over 29 percent in 2023. Even more alarming, without prevention, obesity could reach 41 percent by 2030 in California adults.
(d)Serious chronic weight disease with a BMI formula rating over 30 is recognized as such by major medical organizations, including the American Medical Association since 2013, the American Association of Clinical Endocrinology, the American College of Cardiology, the Endocrine Society, the American Society for Reproductive Medicine, the Society for Cardiovascular Angiography and Interventions, the American Urological Association, and the American College of Surgeons.
(e)(1)Chronic weight disease extends beyond the need to lose pounds but can also contribute to possible cancers and other comorbidities. From 2005 to 2014, several cancers that may be associated with chronic weight disease have increased in the United States, while cancers associated with other health factors decreased.
(2)Chronic weight disease reduces a patients overall cancer-specific survival rate, as well as increases the risk of cancer recurrence.
(3)The 13 types of cancer related to chronic weight disease are:
(A)Adenocarcinoma of the esophagus.
(B)Postmenopausal breast.
(C)Colon and rectal, or colorectal.
(D)Endometrial of the uterus.
(E)Gallbladder.
(F)Gastric cardia, or upper stomach.
(G)Renal cell carcinoma of the kidney.
(H)Liver.
(I)Ovarian.
(J)Pancreatic.
(K)Thyroid.
(L)Meningioma, a type of brain cancer.
(M)Multiple myeloma, a blood cancer.
(4)Chronic weight disease is associated with an increased risk of more than 200 comorbid conditions. Some of those conditions are:
(A)Type 2 diabetes.
(B)High blood pressure.
(C)Heart disease.
(D)Stroke.
(E)Metabolic syndrome.
(F)Fatty liver diseases.
(G)Other types of cancers.
(H)Breathing problems.
(I)Osteoarthritis.
(J)Gout.
(K)Diseases of the gallbladder and pancreas.
(L)Kidney disease.
(M)Pregnancy problems.
(N)Fertility problems.
(O)Sexual function problems.
(P)Mental health problems.
(f)(1)In addition to individual health impacts of chronic weight disease, employee productivity and contributions to Californias economy are impacted by the prevention and management of chronic weight disease.
(2)Chronic weight disease can be related to reduced labor participation and earnings and increased early mortality, absenteeism, disability, and health care costs exceeding $1 billion and a 2.6-percent reduction in the California gross domestic product.
(g)Barriers to the reduction, maintenance, or elimination of chronic weight disease are essentially access and cost.
(h)This act is intended to increase access to the California workforce, starting with state and local employees, to identify, counsel, and treat chronic weight disease, and ensure treatments available through the California Affordable Drug Manufacturing Act of 2020, including pens, vial injections, pills, and patches of glucagon-like peptide-1 (GLP-1) semaglutide, GLP-1 receptor agonist (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products are available at the former Medi-Cal 2025 price, most favored nation price, or a better price.(h)This act is intended to promote access to affordable glucagon-like peptide-1 (GLP-1) weight management medication for Californians.
SEC. 3.Section 22853.5 is added to the Government Code, to read:22853.5.(a)Commencing January 1, 2027, 2028, a health benefit plan or contract that contracts with the board pursuant to this chapter shall offer optional coverage for chronic weight disease management, including nutritional information and pens, vial injections, pills, and patches of glucagon-like peptide-1 (GLP-1) semaglutide, GLP-1 receptor agonist (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products, as part of one of its health plan options. at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration.
(b)Chronic weight disease management covered pursuant to subdivision (a) shall be offered at the cost previously provided to Medi-Cal beneficiaries in the year 2025 or the most favored nation pricing, as set forth in federal Executive Order No. 14297 on May 12, 2025, or better pricing.
(c)Chronic weight disease management covered pursuant to subdivision (a) shall follow United States Food and Drug Administration label indications for usage.
(d)The California Health and Human Services Agency shall make chronic weight disease management medications described in subdivision (a) available to state and local government employers, and shall determine if chronic weight disease management medications described in subdivision (a) shall be made available to all Californians, including enrollees and insureds of licensed health care service plan contracts and health insurance policies, at the cost described in subdivision (b).(d)For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, or tirzepatide.
(e)This section shall remain in effect only until January 1, 2032, and as of that date is repealed.
SEC. 4.Section 127693 of the Health and Safety Code is amended to read:127693.(a)CHHSA shall enter into partnerships resulting in the acquisition of brand name prescription drugs or production, procurement, or distribution of generic prescription drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers as defined in subdivision (b) of Section 1367.50, and pharmacies as defined in Section 4037 of the Business and Professions Code, as appropriate. The generic prescription drugs shall be produced or distributed by a drug company or generic drug manufacturer that is registered with the United States Food and Drug Administration.(b)(1)CHHSA shall only enter into partnerships pursuant to subdivision (a) to acquire brand name prescription drugs or to produce a generic prescription drug at a price that results in savings, targets failures in the market for generic drugs, or improves patient access to affordable medications.(2)For top drugs identified pursuant to the criteria listed in paragraph (5), CHHSA shall determine if viable pathways exist for partnerships to manufacture, procure, or distribute generic prescription drugs by examining the relevant legal, market, policy, and regulatory factors.(3)CHHSA shall consider the following, if applicable, when setting the price of an acquired brand name prescription drug or a generic prescription drug:(A)United States Food and Drug Administration user fees.(B)Abbreviated new drug application acquisition costs amortized over a five-year period.(C)Mandatory rebates.(D)Total contracting and production costs for the drug, including a reasonable amount for administrative, operating, and rate-of-return expenses of the drug company or generic drug manufacturer.(E)Research and development costs attributed to the drug over a five-year period.(F)Other initial start-up costs amortized over a five-year period.(G)The cost previously provided to Medi-Cal beneficiaries in the year 2025 or a lower cost.(H)The cost previously provided as the most favored nation pricing as set forth in federal Executive Order No. 14297 on May 12, 2025.(4)Each drug shall be made available to providers, patients, and purchasers, as appropriate, at a transparent price and without rebates, other than federally required rebates.(5)CHHSA shall prioritize the selection of brand name and generic prescription drugs that have the greatest impact on lowering drug costs to patients, increasing competition and addressing shortages in the prescription drug market, improving public health, or reducing the cost of prescription drugs to public and private purchasers.(c)(1)In identifying brand name prescription drugs to be acquired or generic prescription drugs to be produced, CHHSA shall consider the report produced by the Department of Managed Health Care pursuant to subdivision (b) of Section 1367.243, the report produced by the Department of Insurance pursuant to subdivision (b) of Section 10123.205 of the Insurance Code, and pharmacy spending data from Medi-Cal and other entities for which the state pays the cost of brand name or generic prescription drugs.(2)The partnerships entered into pursuant to subdivision (a) shall include the production of at least one form of insulin and the acquisition or production of pens, vial injections, pills, and patches of glucagon-like peptide-1 (GLP-1) semaglutide, GLP-1 receptor agonist (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products made available at production and dispensing costs, if one does not already exist in the market. Dispensing costs may include related expenses such as transportation, distribution, and market operations. Any partnership shall also consider:(A)Guaranteeing priority access to insulin supply and supply of pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products for the state.(B)Guaranteeing the manufacture of at least four high-priority drugs for California, as identified pursuant to paragraph (5) of subdivision (b).(C)Creating a state brand identifying biosimilar insulin, pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products, and generic prescription drugs sold in California under this section.(3)CHHSA shall prioritize drugs for chronic and high-cost conditions, and shall consider prioritizing those that can be delivered through mail order.(d)CHHSA shall consult with all of the following public and private purchasers, as appropriate, to develop a list of generic prescription drugs to be acquired, manufactured, or distributed through partnerships:(1)The Public Employees Retirement System, the State Department of Health Care Services, the California Health Benefit Exchange (Covered California), the State Department of Public Health, the Department of General Services, and the Department of Corrections and Rehabilitation, or the entities acting on behalf of each of those state purchasers.(2)Licensed health care service plans.(3)Health insurers holding a valid outstanding certificate of authority from the Insurance Commissioner.(4)Hospitals.(e)Before effectuating a partnership pursuant to this section, CHHSA shall consider the volume of each brand name prescription drug or generic prescription drug over a multiyear period to support a market for a lower cost generic prescription drug, if volume is an important factor in driving down the cost of the drug. For partnerships involving procurement, CHHSA shall determine minimum thresholds for procurement of an entitys expected volume of a targeted drug from the company or manufacturer over a defined target period. In making advance commitments, CHHSA may consult with the Statewide Pharmaceutical Program and the California Pharmaceutical Collaborative.(f)The listed entities in paragraphs (2) to (4), inclusive, of subdivision (d) shall not be required to purchase prescription drugs from CHHSA or entities that contract or partner with CHHSA pursuant to this chapter.(g)CHHSA shall not be required to consult with every entity listed in paragraphs (2) to (4), inclusive, of subdivision (d), so long as purchaser engagement includes a reasonable representation from these groups.(h)Any partnership entered into pursuant to this section may include representation and involvement with the governance of the contractor entity.SEC. 4.Section 127697 of the Health and Safety Code is amended to read:127697.In addition to partnerships authorized pursuant to Sections 127692 and 127693, the California Health and Human Services Agency may, subject to an appropriation by the Legislature, enter into partnerships to increase competition, lower prices, and address supply shortages under any of the following circumstances:
(a)For over-the-counter naloxone products. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of over-the-counter naloxone products by an entity that is authorized to do so under federal or state law.
(b)For generic or brand name drugs to address emerging health concerns, including in reproductive health care or care, gender affirming health care. care, or at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration. For purposes of this section, a glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, or tirzepatide. The California Health and Human Services Agency shall also make its best effort to negotiate pricing at or lower than the most favored nation or Medi-Cal.
(c)For the development, production, procurement, or distribution of vaccines, by an entity that is authorized to do so under federal or state law, with the intent that these vaccines be made widely available to public and private purchasers, providers, suppliers, and pharmacies.
(d)For the manufacture, purchase, or distribution of medical supplies or medical devices.
This act shall be known, and may be cited, as the Preventive Treatment Health Care Act.
SEC. 2.Section 1374.6 is added to the Health and Safety Code, to read:1374.6.(a)A large group health care service plan contract issued, amended, or renewed on or after January 1, 2027, shall cover weight loss as a medical condition.(b)A large group health care service plan contract that provides coverage for outpatient prescription drug benefits and is issued, amended, or renewed on or after January 1, 2027, shall include coverage for at least one FDA-approved antiobesity medication.(c)This section does not prohibit a plan from applying utilization management to determine the medical necessity for weight loss under this section if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by a contract.(d)Coverage criteria for FDA-approved antiobesity medications shall not be more restrictive than the FDA-approved indications for those treatments.(e)For purposes of this section, FDA-approved antiobesity medication means a medication approved by the United States Food and Drug Administration with an indication for chronic weight management in patients with obesity.(f)This section does not apply to a specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.(g)This section does not limit existing prescription drug coverage requirements, including the requirements of Section 1300.67.24 of Title 28 of the California Code of Regulations.SEC. 2.The Legislature finds and declares all of the following:
(a)There are approximately 30,000,000 adults 18 years of age and older living in California.
(b)(1)According to the University of California, Los Angeles, California Health Interview Survey, nearly 61 percent of, or more than 24,500,000, California adults 18 to 64 years of age, inclusive, are suffering from chronic weight disease, thereby falling into the combined overweight or obese category.
(2)The body mass index (BMI) is a formula that screens for excess weight relative to height.
(3)The federal Centers for Disease Control and Prevention classifies weight into six categories. The BMI formula used is categorized as follows:
| Underweight | BMI below 18.5 |
| Healthy weight | BMI 18.5 to 24.9 |
| Overweight | BMI 25.0 to 29.9 |
| Class 1 Obesity | BMI 30.0-34.9 |
| Class 2 Obesity | BMI 35.0 to 39.9 |
| Class 3 Obesity | BMI 40.0 and above |
(4)Further, BMI is measured to determine risk for weight-related disease often associated with a waist size of 35 inches or more in women and 40 inches or more in men.
(c)Californians with a greater determination of overweight beyond a BMI higher than 30.0 are clinically described as obese, which has increased from 19.3 percent in 2001 to over 29 percent in 2023. Even more alarming, without prevention, obesity could reach 41 percent by 2030 in California adults.
(d)Serious chronic weight disease with a BMI formula rating over 30 is recognized as such by major medical organizations, including the American Medical Association since 2013, the American Association of Clinical Endocrinology, the American College of Cardiology, the Endocrine Society, the American Society for Reproductive Medicine, the Society for Cardiovascular Angiography and Interventions, the American Urological Association, and the American College of Surgeons.
(e)(1)Chronic weight disease extends beyond the need to lose pounds but can also contribute to possible cancers and other comorbidities. From 2005 to 2014, several cancers that may be associated with chronic weight disease have increased in the United States, while cancers associated with other health factors decreased.
(2)Chronic weight disease reduces a patients overall cancer-specific survival rate, as well as increases the risk of cancer recurrence.
(3)The 13 types of cancer related to chronic weight disease are:
(A)Adenocarcinoma of the esophagus.
(B)Postmenopausal breast.
(C)Colon and rectal, or colorectal.
(D)Endometrial of the uterus.
(E)Gallbladder.
(F)Gastric cardia, or upper stomach.
(G)Renal cell carcinoma of the kidney.
(H)Liver.
(I)Ovarian.
(J)Pancreatic.
(K)Thyroid.
(L)Meningioma, a type of brain cancer.
(M)Multiple myeloma, a blood cancer.
(4)Chronic weight disease is associated with an increased risk of more than 200 comorbid conditions. Some of those conditions are:
(A)Type 2 diabetes.
(B)High blood pressure.
(C)Heart disease.
(D)Stroke.
(E)Metabolic syndrome.
(F)Fatty liver diseases.
(G)Other types of cancers.
(H)Breathing problems.
(I)Osteoarthritis.
(J)Gout.
(K)Diseases of the gallbladder and pancreas.
(L)Kidney disease.
(M)Pregnancy problems.
(N)Fertility problems.
(O)Sexual function problems.
(P)Mental health problems.
(f)(1)In addition to individual health impacts of chronic weight disease, employee productivity and contributions to Californias economy are impacted by the prevention and management of chronic weight disease.
(2)Chronic weight disease can be related to reduced labor participation and earnings and increased early mortality, absenteeism, disability, and health care costs exceeding $1 billion and a 2.6-percent reduction in the California gross domestic product.
(g)Barriers to the reduction, maintenance, or elimination of chronic weight disease are essentially access and cost.
(h)This act is intended to increase access to the California workforce, starting with state and local employees, to identify, counsel, and treat chronic weight disease, and ensure treatments available through the California Affordable Drug Manufacturing Act of 2020, including pens, vial injections, pills, and patches of glucagon-like peptide-1 (GLP-1) semaglutide, GLP-1 receptor agonist (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products are available at the former Medi-Cal 2025 price, most favored nation price, or a better price.
SEC. 3.Section 22853.5 is added to the Government Code, to read:22853.5.(a)Commencing January 1, 2027, a health benefit plan or contract that contracts with the board pursuant to this chapter shall offer optional coverage for chronic weight disease management, including nutritional information and pens, vial injections, pills, and patches of glucagon-like peptide-1 (GLP-1) semaglutide, GLP-1 receptor agonist (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products, as part of one of its health plan options.
(b)Chronic weight disease management covered pursuant to subdivision (a) shall be offered at the cost previously provided to Medi-Cal beneficiaries in the year 2025 or the most favored nation pricing, as set forth in federal Executive Order No. 14297 on May 12, 2025, or better pricing.
(c)Chronic weight disease management covered pursuant to subdivision (a) shall follow United States Food and Drug Administration label indications for usage.
(d)The California Health and Human Services Agency shall make chronic weight disease management medications described in subdivision (a) available to state and local government employers, and shall determine if chronic weight disease management medications described in subdivision (a) shall be made available to all Californians, including enrollees and insureds of licensed health care service plan contracts and health insurance policies, at the cost described in subdivision (b).
(e)This section shall remain in effect only until January 1, 2032, and as of that date is repealed.
SEC. 3.SEC. 4.Section 127693 of the Health and Safety Code is amended to read:127693.(a)CHHSA shall enter into partnerships resulting in the acquisition of brand name prescription drugs or production, procurement, or distribution of generic prescription drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers as defined in subdivision (b) of Section 1367.50, and pharmacies as defined in Section 4037 of the Business and Professions Code, as appropriate. The generic prescription drugs shall be produced or distributed by a drug company or generic drug manufacturer that is registered with the United States Food and Drug Administration.
(b)(1)CHHSA shall only enter into partnerships pursuant to subdivision (a) to acquire brand name prescription drugs or to produce a generic prescription drug at a price that results in savings, targets failures in the market for generic drugs, or improves patient access to affordable medications.
(2)For top drugs identified pursuant to the criteria listed in paragraph (5), CHHSA shall determine if viable pathways exist for partnerships to manufacture, procure, or distribute generic prescription drugs by examining the relevant legal, market, policy, and regulatory factors.
(3)CHHSA shall consider the following, if applicable, when setting the price of an acquired brand name prescription drug or a generic prescription drug:
(A)United States Food and Drug Administration user fees.
(B)Abbreviated new drug application acquisition costs amortized over a five-year period.
(C)Mandatory rebates.
(D)Total contracting and production costs for the drug, including a reasonable amount for administrative, operating, and rate-of-return expenses of the drug company or generic drug manufacturer.
(E)Research and development costs attributed to the drug over a five-year period.
(F)Other initial start-up costs amortized over a five-year period.
(G)The cost previously provided to Medi-Cal beneficiaries in the year 2025 or a lower cost.
(H)The cost previously provided as the most favored nation pricing as set forth in federal Executive Order No. 14297 on May 12, 2025.
(4)Each drug shall be made available to providers, patients, and purchasers, as appropriate, at a transparent price and without rebates, other than federally required rebates.
(5)CHHSA shall prioritize the selection of brand name and generic prescription drugs that have the greatest impact on lowering drug costs to patients, increasing competition and addressing shortages in the prescription drug market, improving public health, or reducing the cost of prescription drugs to public and private purchasers.
(c)(1)In identifying brand name prescription drugs to be acquired or generic prescription drugs to be produced, CHHSA shall consider the report produced by the Department of Managed Health Care pursuant to subdivision (b) of Section 1367.243, the report produced by the Department of Insurance pursuant to subdivision (b) of Section 10123.205 of the Insurance Code, and pharmacy spending data from Medi-Cal and other entities for which the state pays the cost of brand name or generic prescription drugs.
(2)The partnerships entered into pursuant to subdivision (a) shall include the production of at least one form of insulin and the acquisition or production of pens, vial injections, pills, and patches of glucagon-like peptide-1 (GLP-1) semaglutide, GLP-1 receptor agonist (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products made available at production and dispensing costs, if one does not already exist in the market. Dispensing costs may include related expenses such as transportation, distribution, and market operations. Any partnership shall also consider:
(A)Guaranteeing priority access to insulin supply and supply of pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products for the state.
(B)Guaranteeing the manufacture of at least four high-priority drugs for California, as identified pursuant to paragraph (5) of subdivision (b).
(C)Creating a state brand identifying biosimilar insulin insulin, pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products, and generic prescription drugs sold in California under this section.
(3)The partnerships entered into pursuant to subdivision (a) shall include the production of at least one glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist (GLP-1RA) made available at production and dispensing costs, if one does not already exist in the market. Dispensing costs may include related expenses such as transportation, distribution, and market operations. Any partnership shall also consider guaranteeing priority access to GLP-1 or GLP-1RA supply for the state.(4)(3)CHHSA shall prioritize drugs for chronic and high-cost conditions, and shall consider prioritizing those that can be delivered through mail order.
(d)CHHSA shall consult with all of the following public and private purchasers, as appropriate, to develop a list of generic prescription drugs to be manufactured acquired, manufactured, or distributed through partnerships:
(1)The Public Employees Retirement System, the State Department of Health Care Services, the California Health Benefit Exchange (Covered California), the State Department of Public Health, the Department of General Services, and the Department of Corrections and Rehabilitation, or the entities acting on behalf of each of those state purchasers.
(2)Licensed health care service plans.
(3)Health insurers holding a valid outstanding certificate of authority from the Insurance Commissioner.
(4)Hospitals.
(e)Before effectuating a partnership pursuant to this section, CHHSA shall consider the volume of each brand name prescription drug or generic prescription drug over a multiyear period to support a market for a lower cost generic prescription drug, if volume is an important factor in driving down the cost of the drug. For partnerships involving procurement, CHHSA shall determine minimum thresholds for procurement of an entitys expected volume of a targeted drug from the company or manufacturer over a defined target period. In making advance commitments, CHHSA may consult with the Statewide Pharmaceutical Program and the California Pharmaceutical Collaborative.
(f)The listed entities in paragraphs (2) to (4), inclusive, of subdivision (d) shall not be required to purchase prescription drugs from CHHSA or entities that contract or partner with CHHSA pursuant to this chapter.
(g)CHHSA shall not be required to consult with every entity listed in paragraphs (2) to (4), inclusive, of subdivision (d), so long as purchaser engagement includes a reasonable representation from these groups.
(h)Any partnership entered into pursuant to this section may include representation and involvement with the governance of the contractor entity.
SEC. 4.Section 130514 is added to the Health and Safety Code, immediately following Section 130513, to read:130514.An employer with 100 or more employees may negotiate directly with a drug manufacturer to provide a discount for a glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist.SEC. 5.Section 10123.62 is added to the Insurance Code, to read:10123.62.(a)A large group health insurance policy issued, amended, or renewed on or after January 1, 2027, shall cover weight loss as a medical condition.(b)This section does not apply to a specialized health insurance policy that covers only dental or vision benefits or a Medicare supplement policy.SEC. 6.Section 2805 is added to the Labor Code, to read:2805.An employer with 100 or more employees shall offer its employees access to all of the following:(a)Exercise programs, gym memberships, or both.(b)Nutrition services.(c)Coverage for a glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist.SEC. 7.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.This act shall be known, and may be cited, as the Preventive Care Act.
SEC. 2.Section 1374.6 is added to the Health and Safety Code, to read:1374.6.(a)A large group health care service plan contract issued, amended, or renewed on or after January 1, 2027, shall cover weight loss as a medical condition.
(b)A large group health care service plan contract that provides coverage for outpatient prescription drug benefits and is issued, amended, or renewed on or after January 1, 2027, shall include coverage for at least one FDA-approved antiobesity medication.
(c)This section does not prohibit a plan from applying utilization management to determine the medical necessity for weight loss under this section if appropriateness and medical necessity determinations are made in the same manner as those determinations are made for the treatment of any other illness, condition, or disorder covered by a contract.
(d)Coverage criteria for FDA-approved antiobesity medications shall not be more restrictive than the FDA-approved indications for those treatments.
(e)For purposes of this section, FDA-approved antiobesity medication means a medication approved by the United States Food and Drug Administration with an indication for chronic weight management in patients with obesity.
(f)This section does not apply to a specialized health care service plan contract that covers only dental or vision benefits or a Medicare supplement contract.
(g)This section does not limit existing prescription drug coverage requirements, including the requirements of Section 1300.67.24 of Title 28 of the California Code of Regulations.
SEC. 3.Section 127693 of the Health and Safety Code is amended to read:127693.(a)CHHSA shall enter into partnerships resulting in the production, procurement, or distribution of generic prescription drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers as defined in subdivision (b) of Section 1367.50, and pharmacies as defined in Section 4037 of the Business and Professions Code, as appropriate. The generic prescription drugs shall be produced or distributed by a drug company or generic drug manufacturer that is registered with the United States Food and Drug Administration.
(b)(1)CHHSA shall only enter into partnerships pursuant to subdivision (a) to produce a generic prescription drug at a price that results in savings, targets failures in the market for generic drugs, or improves patient access to affordable medications.
(2)For top drugs identified pursuant to the criteria listed in paragraph (5), CHHSA shall determine if viable pathways exist for partnerships to manufacture, procure, or distribute generic prescription drugs by examining the relevant legal, market, policy, and regulatory factors.
(3)CHHSA shall consider the following, if applicable, when setting the price of a generic prescription drug:
(A)United States Food and Drug Administration user fees.
(B)Abbreviated new drug application acquisition costs amortized over a five-year period.
(C)Mandatory rebates.
(D)Total contracting and production costs for the drug, including a reasonable amount for administrative, operating, and rate-of-return expenses of the drug company or generic drug manufacturer.
(E)Research and development costs attributed to the drug over a five-year period.
(F)Other initial start-up costs amortized over a five-year period.
(4)Each drug shall be made available to providers, patients, and purchasers, as appropriate, at a transparent price and without rebates, other than federally required rebates.
(5)CHHSA shall prioritize the selection of generic prescription drugs that have the greatest impact on lowering drug costs to patients, increasing competition and addressing shortages in the prescription drug market, improving public health, or reducing the cost of prescription drugs to public and private purchasers.
(c)(1)In identifying generic prescription drugs to be produced, CHHSA shall consider the report produced by the Department of Managed Health Care pursuant to subdivision (b) of Section 1367.243, the report produced by the Department of Insurance pursuant to subdivision (b) of Section 10123.205 of the Insurance Code, and pharmacy spending data from Medi-Cal and other entities for which the state pays the cost of generic prescription drugs.
(2)The partnerships entered into pursuant to subdivision (a) shall include the production of at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Dispensing costs may include related expenses such as transportation, distribution, and market operations. Any partnership shall also consider:
(A)Guaranteeing priority access to insulin supply for the state.
(B)Guaranteeing the manufacture of at least four high-priority drugs for California, as identified pursuant to paragraph (5) of subdivision (b).
(C)Creating a state brand identifying biosimilar insulin and generic prescription drugs sold in California under this section.
(3)The partnerships entered into pursuant to subdivision (a) shall include the production of at least one glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist (GLP-1RA) made available at production and dispensing costs, if one does not already exist in the market. Dispensing costs may include related expenses such as transportation, distribution, and market operations. Any partnership shall also consider guaranteeing priority access to GLP-1 or GLP-1RA supply for the state.
(3)(4)CHHSA shall prioritize drugs for chronic and high-cost conditions, and shall consider prioritizing those that can be delivered through mail order.
(d)CHHSA shall consult with all of the following public and private purchasers, as appropriate, to develop a list of generic prescription drugs to be manufactured or distributed through partnerships:
(1)The Public Employees Retirement System, the State Department of Health Care Services, the California Health Benefit Exchange (Covered California), the State Department of Public Health, the Department of General Services, and the Department of Corrections and Rehabilitation, or the entities acting on behalf of each of those state purchasers.
(2)Licensed health care service plans.
(3)Health insurers holding a valid outstanding certificate of authority from the Insurance Commissioner.
(4)Hospitals.
(e)Before effectuating a partnership pursuant to this section, CHHSA shall consider the volume of each generic prescription drug over a multiyear period to support a market for a lower cost generic prescription drug, if volume is an important factor in driving down the cost of the drug. For partnerships involving procurement, CHHSA shall determine minimum thresholds for procurement of an entitys expected volume of a targeted drug from the company or manufacturer over a defined target period. In making advance commitments, CHHSA may consult with the Statewide Pharmaceutical Program and the California Pharmaceutical Collaborative.
(f)The listed entities in paragraphs (2) to (4), inclusive, of subdivision (d) shall not be required to purchase prescription drugs from CHHSA or entities that contract or partner with CHHSA pursuant to this chapter.
(g)CHHSA shall not be required to consult with every entity listed in paragraphs (2) to (4), inclusive, of subdivision (d), so long as purchaser engagement includes a reasonable representation from these groups.
(h)Any partnership entered into pursuant to this section may include representation and involvement with the governance of the contractor entity.
SEC. 4.Section 130514 is added to the Health and Safety Code, immediately following Section 130513, to read:130514.An employer with 100 or more employees may negotiate directly with a drug manufacturer to provide a discount for a glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist.
SEC. 5.Section 10123.62 is added to the Insurance Code, to read:10123.62.(a)A large group health insurance policy issued, amended, or renewed on or after January 1, 2027, shall cover weight loss as a medical condition.
(b)This section does not apply to a specialized health insurance policy that covers only dental or vision benefits or a Medicare supplement policy.
SEC. 6.Section 2805 is added to the Labor Code, to read:2805.An employer with 100 or more employees shall offer its employees access to all of the following:
(a)Exercise programs, gym memberships, or both.
(b)Nutrition services.
(c)Coverage for a glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist.
SEC. 7.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Sep 28, 2026 | Chaptered by Secretary of State. Chapter 725, Statutes of 2026. |
| Sep 28, 2026 | Approved by the Governor. |
| Sep 3, 2026 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 27, 2026 | Assembly amendments concurred in. (Ayes 40. Noes 0. Page 5987.) Ordered to engrossing and enrolling. |
| Aug 27, 2026 | Assembly amendments concurred in. (Ayes 39. Noes 0.) Ordered to engrossing and enrolling. |
| Aug 26, 2026 | Ordered to special consent calendar. |
| Aug 24, 2026 | In Senate. Concurrence in Assembly amendments pending. |
| Aug 24, 2026 | Read third time. Passed. (Ayes 77. Noes 0. Page 6418.) Ordered to the Senate. |
| Aug 24, 2026 | Read third time. Passed. Ordered to the Senate. |
| Aug 20, 2026 | Ordered to third reading. |
| Aug 20, 2026 | Read third time and amended. |
| Aug 13, 2026 | Read second time. Ordered to third reading. |
| Aug 13, 2026 | From committee: Do pass. (Ayes 14. Noes 0.) (August 13). |
| Aug 13, 2026 | Assembly Rule 63 suspended. |
| Aug 5, 2026 | August 5 set for first hearing. Placed on suspense file. |
| Jun 22, 2026 | Re-referred to Com. on APPR. pursuant to Assembly Rule 96. |
| Jun 18, 2026 | Read second time and amended. Re-referred to Com. on P. E. & R. |
| Jun 17, 2026 | From committee: Do pass as amended and re-refer to Com. on P. E. & R. (Ayes 15. Noes 0.) (June 16). |
| Jun 4, 2026 | Referred to Coms. on HEALTH and P. E. & R. |
| May 27, 2026 | In Assembly. Read first time. Held at Desk. |
| May 27, 2026 | Read third time. Passed. (Ayes 39. Noes 0. Page 4499.) Ordered to the Assembly. |
| May 27, 2026 | Read third time. Passed. (Ayes 39. Noes 0.) Ordered to the Assembly. |
| May 18, 2026 | Read second time. Ordered to third reading. |
| May 14, 2026 | From committee: Do pass as amended. (Ayes 7. Noes 0. Page 4264.) (May 14). |
| May 14, 2026 | Read second time and amended. Ordered to second reading. |
| May 14, 2026 | From committee: Do pass as amended. (Ayes 7. Noes 0.) (May 14). |
| May 8, 2026 | Set for hearing May 14. |
| May 4, 2026 | May 4 hearing: Placed on APPR. suspense file. |
| Apr 28, 2026 | Set for hearing May 4. |
| Apr 23, 2026 | Read second time and amended. Re-referred to Com. on APPR. |
| Apr 22, 2026 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 5. Noes 0. Page 4013.) (April 22). |
| Apr 22, 2026 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 5. Noes 0.) (April 22). |
| Apr 16, 2026 | From committee: Do pass and re-refer to Com. on L., P.E. & R. (Ayes 10. Noes 0. Page 3901.) (April 15). Re-referred to Com. on L., P.E. & R. |
| Apr 16, 2026 | From committee: Do pass and re-refer to Com. on L., P.E. & R. (Ayes 10. Noes 0.) (April 15). Re-referred to Com. on L., P.E. & R. |
| Apr 15, 2026 | Set for hearing April 22 in L., P.E. & R. pending receipt. |
| Mar 27, 2026 | Set for hearing April 15. |
| Mar 24, 2026 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Feb 26, 2026 | Referred to Coms. on HEALTH and L., P.E. & R. |
| Feb 17, 2026 | From printer. May be acted upon on or after March 16. |
| Feb 13, 2026 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 27, 2026 | Special Consent SB1089 Richardson et al. | Senate Floor |
Passed |
|
| Aug 24, 2026 | SB 1089 Richardson Senate Third Reading By Wicks | Assembly Floor |
Passed |
|
| Aug 13, 2026 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Jun 16, 2026 | Do pass as amended and be re-referred to the Committee on [Public Employment and Retirement] | Assembly Standing Committee on Health |
Passed |
|
| May 27, 2026 | Senate 3rd Reading SB1089 Richardson | Senate Floor |
Passed |
|
| May 14, 2026 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| May 4, 2026 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 22, 2026 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Labor, Public Employment and Retirement |
Passed |
|
| Apr 15, 2026 | Do pass, but first be re-referred to the Committee on [Labor, Public Employment and Retirement ] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| 1 individual | ** Against | |
| American Diabetes Association | ** Support | |
| California Academy Of Family Physicians | ** Support | |
| California Black Health Network | ** Support | |
| California Chronic Care Coalition | ** Support | |
| California Life Sciences | ** Support | |
| California Life Sciences (CLS) | ** Support | |
| California Orthopedic Association | ** Support | |
| California Primary Care Association | ** Support | |
| California Rheumatology Alliance | ** Support | |
| California Small Business Association | ** Against | |
| Los Angeles County Medical Association | ** Support | |
| Los Angeles LGBT Center | ** Support | |
| One individual | ** Support |
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | SB 1089 |
UNFINISHED BUSINESS
Bill No: SB 1089
Author: Richardson (D), et al.
Amended: 8/20/26
Vote: 21
SENATE HEALTH COMMITTEE: 10-0, 4/15/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Menjivar, Padilla, Rubio, Smallwood-Cuevas
NO VOTE RECORDED: Pérez
SENATE LABOR, PUB. EMP. & RET. COMMITTEE: 5-0, 4/22/26
AYES: Smallwood-Cuevas, Strickland, Cortese, Durazo, Laird
SENATE APPROPRIATIONS COMMITTEE: 7-0, 5/14/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
SENATE FLOOR: 39-0, 5/27/26
AYES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Durazo, Gonzalez, Grayson, Grove, Hurtado, Jones, Laird, Limón, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Reyes, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
NO VOTE RECORDED: Dahle
ASSEMBLY FLOOR: 77-0, 8/24/26 - See last page for vote
SUBJECT: Preventive Treatment Health Care Act
SOURCE: Author
DIGEST:
This bill adds at least one glucagon-like peptide-1 (GLP-1) antiobesity weight medication approved by the federal U.S. Food and Drug Administration (FDA) to existing authority granted to the California Health and Human Services Agency under the California Affordable Drug Manufacturing Act of 2020 (also referred to as CalRx), for purposes of entering into partnerships, if needed, to increase competition, lower prices, and address supply shortages.
Assembly Amendments delete provisions that would have required a health benefit plan contract with the California Public Employees’ Retirement System to offer coverage for chronic weight disease management or to treat obesity or overweight persons, including nutritional information and at least one GLP-1 weight medication approved by the FDA, with a sunset provision of January 1, 2031. Includes in the definition of GLP-1 antiobesity weight management medication, future weight management medications in this category.
ANALYSIS:
Existing law:
- Establishes the California Health and Human Services Agency (CHHSA), which consists of the following departments and offices: Aging, Child Support Services, Community Services and Development, Developmental Services, Health Care Access and Information (HCAI), Health Care Services, Managed Health Care (DMHC), Public Health, Rehabilitation, Social Services, State Hospitals, the Center for Data Insights and Innovation, the Emergency Medical Services Authority, the Office of Technology and Solutions Integration, the Office of Law Enforcement Support, the Office of the Surgeon General, the Office of Youth and Community Restoration, and the State Council on Developmental Disabilities. [Government Code (GOV) §12803 and §12806]
- Requires CHHSA or its departments, under the California Affordable Drug Manufacturing Act of 2020, to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs, as specified, and to increase patient access to affordable drugs. This program is referred to as CalRx. [Health and Safety Code (HSC) §127692(a)]
- Requires CalRx to enter into partnerships resulting in the production, procurement or distribution of generic drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Requires the generic drugs to be produced or distributed by a drug company or generic drug manufacturer that is registered with the FDA. Requires CalRx to only enter into partnerships to produce generic drugs at a price that results in savings, targets failures in the market for generic drugs, and improves patient access to affordable medications. [HSC §127693(a) and §127693(b)]
- Requires, in identifying generic prescription drugs to be produced, CHHSA to consider reports on prescription drug costs published by DMHC and the Department of Insurance, and pharmacy spending data from Medi-Cal and other entities for which the state pays the cost of generic prescription drugs. Requires the partnerships to include the production of at least one form of insulin, provided that a viable pathway for manufacturing a more affordable form of insulin exists. [HSC §127693(c)(1) and (2)]
- Authorizes CalRx, subject to appropriation, to enter into partnerships to increase competition, lower prices, and address supply shortages for: over-the-counter naloxone products; generic or brand name drugs to address emerging health concerns, including reproductive health care or gender affirming health care; development, production, procurement, or distribution of vaccines, as specified; and, the manufacture, purchase, or distribution of medical supplies or medication devices. [HSC §127697]
This bill:
- States intent to increase access to affordable glucagoin-like-peptide-1 (GLP-1) weight management medications in California.
- Authorizes CHHSA to, subject to an appropriation by the Legislature, enter into partnerships, if needed, to increase competition, lower prices, and address supply shortages for at least one GLP-1 antiobesity medication approved by the FDA.
- Defines GLP-1 antiobesity medication approved by the FDA includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medications in this category.
- Requires CHHSA to also establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
Comments
According to the author of this bill:
Chronic weight disease is a serious problem in the United States. There are approximately 24.5 million adults between the ages of 18-64 years living in California. According to UCLA’s California Health Interview Survey, nearly 61% of California adults fall into the combined overweight/obese category, which is associated with 200 morbid conditions, including 13 types of cancer. Chronic weight management can be related to reduced labor participation and earnings, increased early mortality, absenteeism, disability and healthcare costs exceeding $1 billion and a 2.6% reduction in the California Gross Domestic Product. California Public Employees’ Retirement System (CalPERS) health insurance covers more than 1.5 million public employees. As the largest purchaser of public employee health benefits in California, the program provides coverage for over 1,200 public agencies and schools. This bill will require CalPERS to offer GLP-1s as an optional benefit through their health plan to reduce chronic weight management and reduce overall employer costs. Federal Executive Order authorized the Most-Favored-Nation Prescription Drug Pricing. This included offering GLP-1 medications at negotiated rate of $149 - $350 per month. These lower prices will be available through the Trump Rx platform. With CalRx offering affordable cost of $245 per month, 20% of California adults will reduce costs and employees will be more productive creating workforce savings.
Background
The Medicaid Drug Rebate Program provides a rebate to states for a portion of the Medicaid payment for each drug. The rebate is shared with the federal government. In return most manufacturer’s drugs are covered under state Medicaid programs. Some drugs or classes of drugs may be excluded from coverage, including drugs for weight loss. As of January 2026, 13 states covered GLP-1s for obesity treatment under Medicaid. Beginning in 2022, California consolidated pharmacy benefits under one system called Medi-Cal Rx, where the state pays for all drug claims on a fee-for-service basis, including for people in Medi-Cal managed care plans. Because of significant growth in the state’s pharmacy spending including for GLP-1 Agonists, in October 2025 pursuant to the enacted 2025-26 California state budget, Medi-Cal Rx announced that it will continue to cover GLP-1 medication when used for indications approved by the FDA, such as treating type 2 diabetes, atherosclerotic cardiovascular disease, and chronic kidney disease. Three drugs for weight loss or weight-loss indications would no longer be covered effective January 1, 2026. Coverage would continue for certain FDA-approved indications and for people younger than 21 years of age pursuant to the federal Early and Periodic Screening, Diagnostic, and Treatment benefit. The Budget Act of 2025 included General Fund savings of $85 million, increasing to $680 million annually by 2028-29 from the elimination of Medi-Cal coverage of GLP-1 drugs.
CalRx program currently produces Insulin Glargine at $55 for a five-pack of 3mLpens and leverages the state’s purchasing power to buy naloxone at a reduced cost (twin pack of over-the-counter naloxone nasal spray for $19). CalRx also plans to launch a centralized ordering system to supply California schools with albuterol inhalers and single-use disposable spacers at no cost over a three-year period beginning this summer. At an April 9, 2026, Senate Budget Health and Human Services Subcommittee hearing HCAI’s director indicated that GLP-1 antiobesity medications are among the drugs CalRx is considering for future inclusion.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Assembly Appropriations Committee, HCAI estimates one-time costs of several million dollars to establish partnerships for development, distribution, or procurement of a GLP-1 and ongoing costs, likely several thousand dollars per year, for two staff positions (General Fund). Eventually, sales of the drug should cover the costs of manufacturing or contracting.
SUPPORT: (Verified 8/24/26)
American Diabetes Association
California Academy of Family Physicians
California Black Health Network
California Chronic Care Coalition
California Life Sciences
California Orthopedic Association
California Primary Care Association
California Rheumatology Alliance
Los Angeles County Medical Association
Los Angeles LGBT Center
One individual
OPPOSITION: (Verified 8/24/26)
1 individual
ARGUMENTS IN SUPPORT: The American Diabetes Association (ADA) writes that GLP-1 and GLP-1RA medications have proven transformative in the management of type 2 diabetes and obesity, improving blood glucose control, reducing cardiovascular risk, and contributing to meaningful weight reduction, yet access to these medications remains severely limited for many Californians due to inconsistent insurance coverage. The ADA supports efforts that bring evidence-based, life-saving diabetes therapies within reach of all who need them—particularly those in low-income and working-class populations who face the greatest barriers to consistent care. The ADA indicates this bill aligns with their mission to prevent type 2 diabetes and to improve the lives of all people affected by it. California Primary Care Association (CPCA) Advocates write this bill is particularly important for community health centers and their patients. CPCA Advocates indicates the high cost of these drugs has placed them out of reach for many patients who are uninsured or underinsured. They write that this bill will help community health clinics provide more effective, evidence-based care.
ARGUMENTS IN OPPOSITION: An individual writing on behalf of the California Small Business Association writes to express opposition to “costly health care mandates that are threatening the sustainability of employer-sponsored health care coverage” and lists four bills including this bill.
ASSEMBLY FLOOR: 77-0 8/24/26
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Chen, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Flora, Fong, Gabriel, Garcia, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lackey, Lee, Lowenthal, Macedo, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Celeste Rodriguez, Michelle Rodriguez, Rogers, Blanca Rubio, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NO VOTE RECORDED: McKinnor, Tangipa
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
9/21/26 15:56:12
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | SB 1089 |
UNFINISHED BUSINESS
Bill No: SB 1089
Author: Richardson (D), et al.
Amended: 8/20/26
Vote: 21
SENATE HEALTH COMMITTEE: 10-0, 4/15/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Menjivar, Padilla, Rubio, Smallwood-Cuevas
NO VOTE RECORDED: Pérez
SENATE LABOR, PUB. EMP. & RET. COMMITTEE: 5-0, 4/22/26
AYES: Smallwood-Cuevas, Strickland, Cortese, Durazo, Laird
SENATE APPROPRIATIONS COMMITTEE: 7-0, 5/14/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
SENATE FLOOR: 39-0, 5/27/26
AYES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Durazo, Gonzalez, Grayson, Grove, Hurtado, Jones, Laird, Limón, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Reyes, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
NO VOTE RECORDED: Dahle
ASSEMBLY FLOOR: Passed, 8/24/26
SUBJECT: Preventive Treatment Health Care Act
SOURCE: Author
DIGEST:
This bill adds at least one glucagon-like peptide-1 (GLP-1) antiobesity weight medication approved by the federal U.S. Food and Drug Administration (FDA) to existing authority granted to the California Health and Human Services Agency under the California Affordable Drug Manufacturing Act of 2020 (also referred to as CalRx), for purposes of entering into partnerships, if needed, to increase competition, lower prices, and address supply shortages.
Assembly Amendments delete provisions that would have required a health benefit plan contract with the California Public Employees’ Retirement System to offer coverage for chronic weight disease management or to treat obesity or overweight persons, including nutritional information and at least one GLP-1 weight medication approved by the FDA, with a sunset provision of January 1, 2031. Includes in the definition of GLP-1 antiobesity weight management medication, future weight management medications in this category.
ANALYSIS:
Existing law:
- Establishes the California Health and Human Services Agency (CHHSA), which consists of the following departments and offices: Aging, Child Support Services, Community Services and Development, Developmental Services, Health Care Access and Information (HCAI), Health Care Services, Managed Health Care (DMHC), Public Health, Rehabilitation, Social Services, State Hospitals, the Center for Data Insights and Innovation, the Emergency Medical Services Authority, the Office of Technology and Solutions Integration, the Office of Law Enforcement Support, the Office of the Surgeon General, the Office of Youth and Community Restoration, and the State Council on Developmental Disabilities. [Government Code (GOV) §12803 and §12806]
- Requires CHHSA or its departments, under the California Affordable Drug Manufacturing Act of 2020, to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs, as specified, and to increase patient access to affordable drugs. This program is referred to as CalRx. [Health and Safety Code (HSC) §127692(a)]
- Requires CalRx to enter into partnerships resulting in the production, procurement or distribution of generic drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Requires the generic drugs to be produced or distributed by a drug company or generic drug manufacturer that is registered with the FDA. Requires CalRx to only enter into partnerships to produce generic drugs at a price that results in savings, targets failures in the market for generic drugs, and improves patient access to affordable medications. [HSC §127693(a) and §127693(b)]
- Requires, in identifying generic prescription drugs to be produced, CHHSA to consider reports on prescription drug costs published by DMHC and the Department of Insurance, and pharmacy spending data from Medi-Cal and other entities for which the state pays the cost of generic prescription drugs. Requires the partnerships to include the production of at least one form of insulin, provided that a viable pathway for manufacturing a more affordable form of insulin exists. [HSC §127693(c)(1) and (2)]
- Authorizes CalRx, subject to appropriation, to enter into partnerships to increase competition, lower prices, and address supply shortages for: over-the-counter naloxone products; generic or brand name drugs to address emerging health concerns, including reproductive health care or gender affirming health care; development, production, procurement, or distribution of vaccines, as specified; and, the manufacture, purchase, or distribution of medical supplies or medication devices. [HSC §127697]
This bill:
- States intent to increase access to affordable glucagoin-like-peptide-1 (GLP-1) weight management medications in California.
- Authorizes CHHSA to, subject to an appropriation by the Legislature, enter into partnerships, if needed, to increase competition, lower prices, and address supply shortages for at least one GLP-1 antiobesity medication approved by the FDA.
- Defines GLP-1 antiobesity medication approved by the FDA includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medications in this category.
- Requires CHHSA to also establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
Comments
According to the author of this bill:
Chronic weight disease is a serious problem in the United States. There are approximately 24.5 million adults between the ages of 18-64 years living in California. According to UCLA’s California Health Interview Survey, nearly 61% of California adults fall into the combined overweight/obese category, which is associated with 200 morbid conditions, including 13 types of cancer. Chronic weight management can be related to reduced labor participation and earnings, increased early mortality, absenteeism, disability and healthcare costs exceeding $1 billion and a 2.6% reduction in the California Gross Domestic Product. California Public Employees’ Retirement System (CalPERS) health insurance covers more than 1.5 million public employees. As the largest purchaser of public employee health benefits in California, the program provides coverage for over 1,200 public agencies and schools. This bill will require CalPERS to offer GLP-1s as an optional benefit through their health plan to reduce chronic weight management and reduce overall employer costs. Federal Executive Order authorized the Most-Favored-Nation Prescription Drug Pricing. This included offering GLP-1 medications at negotiated rate of $149 - $350 per month. These lower prices will be available through the Trump Rx platform. With CalRx offering affordable cost of $245 per month, 20% of California adults will reduce costs and employees will be more productive creating workforce savings.
Background
The Medicaid Drug Rebate Program provides a rebate to states for a portion of the Medicaid payment for each drug. The rebate is shared with the federal government. In return most manufacturer’s drugs are covered under state Medicaid programs. Some drugs or classes of drugs may be excluded from coverage, including drugs for weight loss. As of January 2026, 13 states covered GLP-1s for obesity treatment under Medicaid. Beginning in 2022, California consolidated pharmacy benefits under one system called Medi-Cal Rx, where the state pays for all drug claims on a fee-for-service basis, including for people in Medi-Cal managed care plans. Because of significant growth in the state’s pharmacy spending including for GLP-1 Agonists, in October 2025 pursuant to the enacted 2025-26 California state budget, Medi-Cal Rx announced that it will continue to cover GLP-1 medication when used for indications approved by the FDA, such as treating type 2 diabetes, atherosclerotic cardiovascular disease, and chronic kidney disease. Three drugs for weight loss or weight-loss indications would no longer be covered effective January 1, 2026. Coverage would continue for certain FDA-approved indications and for people younger than 21 years of age pursuant to the federal Early and Periodic Screening, Diagnostic, and Treatment benefit. The Budget Act of 2025 included General Fund savings of $85 million, increasing to $680 million annually by 2028-29 from the elimination of Medi-Cal coverage of GLP-1 drugs.
CalRx program currently produces Insulin Glargine at $55 for a five-pack of 3mLpens and leverages the state’s purchasing power to buy naloxone at a reduced cost (twin pack of over-the-counter naloxone nasal spray for $19). CalRx also plans to launch a centralized ordering system to supply California schools with albuterol inhalers and single-use disposable spacers at no cost over a three-year period beginning this summer. At an April 9, 2026, Senate Budget Health and Human Services Subcommittee hearing HCAI’s director indicated that GLP-1 antiobesity medications are among the drugs CalRx is considering for future inclusion.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Assembly Appropriations Committee, HCAI estimates one-time costs of several million dollars to establish partnerships for development, distribution, or procurement of a GLP-1 and ongoing costs, likely several thousand dollars per year, for two staff positions (General Fund). Eventually, sales of the drug should cover the costs of manufacturing or contracting.
SUPPORT: (Verified 8/24/26)
American Diabetes Association
California Academy of Family Physicians
California Black Health Network
California Chronic Care Coalition
California Life Sciences
California Orthopedic Association
California Primary Care Association
California Rheumatology Alliance
Los Angeles County Medical Association
Los Angeles LGBT Center
One individual
OPPOSITION: (Verified 8/24/26)
1 individual
ARGUMENTS IN SUPPORT: The American Diabetes Association (ADA) writes that GLP-1 and GLP-1RA medications have proven transformative in the management of type 2 diabetes and obesity, improving blood glucose control, reducing cardiovascular risk, and contributing to meaningful weight reduction, yet access to these medications remains severely limited for many Californians due to inconsistent insurance coverage. The ADA supports efforts that bring evidence-based, life-saving diabetes therapies within reach of all who need them—particularly those in low-income and working-class populations who face the greatest barriers to consistent care. The ADA indicates this bill aligns with their mission to prevent type 2 diabetes and to improve the lives of all people affected by it. California Primary Care Association (CPCA) Advocates write this bill is particularly important for community health centers and their patients. CPCA Advocates indicates the high cost of these drugs has placed them out of reach for many patients who are uninsured or underinsured. They write that this bill will help community health clinics provide more effective, evidence-based care.
ARGUMENTS IN OPPOSITION: An individual writing on behalf of the California Small Business Association writes to express opposition to “costly health care mandates that are threatening the sustainability of employer-sponsored health care coverage” and lists four bills including this bill.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/24/26 17:06:59
**** END ****
SENATE THIRD READING
STR Bill Id:SB 1089
Author:(Richardson)
As Amended Ver:August 20, 2026
Majority vote
SUMMARY
Authorizes, subject to appropriation, the California Health and Human Services Agency (CalHHS) to enter into partnerships under CalRx for glucagon-like peptide-1 (GLP-1) medications.
Major Provisions
- Specifies that a GLP-1 approved by the U.S. Food and Drug Administration (FDA) includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide, and future weight management medication.
- Requires CalHHS to establish distribution partners, if needed, and make its best effort to negotiate pricing at or lower than the 2025 cost to Medi-Cal beneficiaries.
- Makes findings and declarations related to chronic weight disease.
COMMENTS
Obesity is a chronic health condition characterized by an increase in the size and amount of fat cells in the body. Health care providers screen for obesity by calculating patients' body mass index (BMI), which takes into account an individual's height and weight. Adults with a BMI of 25 to <30 are categorized as overweight and those with a BMI of 30 or higher are categorized as obese. There are many health consequences of obesity such as an increased risk of heart disease, diabetes, respiratory issues, musculoskeletal disorders, and certain cancers, as well as reduced life expectancy. Causes of obesity are multi-faceted and can include lifestyle habits, environment, stress, health conditions and certain medications, socioeconomic factors, and individual characteristics such as genetics and metabolism. Overall, it is estimated that 15.2% of adolescents aged 12 to 17 years and 27.8% of adults aged 18 to 64 years with private health insurance in California have BMIs that categorize them as having obesity.
Recent elimination of GLP-1 coverage in Medi-Cal. California's Medi-Cal program had previously opted to cover GLP-1 medications with an FDA indication for weight management, with quantity limits and labeler restrictions. However, this coverage was eliminated as of December 31, 2025. In 2024, the state reimbursed more than $1.6 billion for two GLP-1 drugs, representing approximately 10% of Medi-Cal's total pharmacy spending. Coverage for GLP-1 medications for Medi-Cal beneficiaries with other FDA-approved indications for GLP-1 medications (e.g., diabetes) remains intact.
CalRx. To help reduce the cost of prescription drugs in state programs and to consumers, the state recently created the CalRx program at the Department of Health Care Access and Information (HCAI). Established by SB 852 (Pan), Chapter 207, Statutes of 2020, the program aims to reduce the cost of drugs by expanding the availability of low‑cost generics in the market. According to the Legislative Analyst's Office (LAO), CalRx accomplishes this objective by entering into partnerships with private entities to distribute or manufacture generic drugs. Before entering into these partnerships, HCAI must ensure they result in savings, address market failures, improve patient access, and are viable. The Legislature has directed HCAI to work on two key drug initiatives through CalRx, insulin and naloxone. CalRx has executed contracts for both drugs, offering an over‑the‑counter naloxone nasal spray product at $24 for each twin pack and a biosimilar insulin pen at $55 for a five-pack of 3mL pens.
According to the Author
Chronic weight disease is a serious problem in the United States. The author states that there are approximately 24.5 million adults between the ages of 18-64 years living in California. The author continues that according to UCLA's California Health Interview Survey, nearly 61% of California adults fall into the combined overweight/obese category, which is associated with 200 morbid conditions, including 13 types of cancer. The author states that chronic weight management can be related to a reduced labor participation, earnings, increased early mortality, absenteeism, disability, and healthcare costs exceeding $1 billion and a 2.6% reduction in the California Gross Domestic Product.
Arguments in Support
California Life Sciences (CLS) supports this bill, stating that it is an important step toward ensuring that the transformative GLP-1 therapies California's biopharmaceutical industry has helped develop can reach the patients who need them most. CLS continues that the development of GLP-1 receptor agonists and related therapies represents one of the most significant breakthroughs in metabolic medicine in decades, yet cost and access remain the primary barriers preventing Californians from benefiting from these innovations. CLS states that this bill ensures that FDA approval and clinical validation translate into real patient access, fulfilling the promise of the regulatory pathway and supporting the commercial viability of treatments that required enormous scientific and financial investment to bring to market. CLS continues that it positions California as a state where breakthrough therapies reach patients equitably — reinforcing the case for continued innovation investment in metabolic and preventive medicine and signaling to the broader industry that California rewards scientific progress with meaningful policy.
Arguments in Opposition
None to the current version of the bill.
FISCAL COMMENTS
According to the Assembly Committee on Appropriations, HCAI estimates one-time costs of several million dollars to establish partnerships for development, distribution, or procurement of a GLP-1 and ongoing costs, likely several thousand dollars per year, for two staff positions (General Fund). Eventually, sales of the drug should cover the costs of manufacturing or contracting.
VOTES
SENATE FLOOR: 39-0-1
YES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Durazo, Gonzalez, Grayson, Grove, Hurtado, Jones, Laird, Limón, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Reyes, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
ABS, ABST OR NV: Dahle
ASM HEALTH: 15-0-1
YES: Bonta, Chen, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Mark González, Patel, Patterson, Celeste Rodriguez, Sanchez, Schiavo, Sharp-Collins, Stefani
ABS, ABST OR NV: Johnson
ASM APPROPRIATIONS: 14-0-1
YES: Wicks, Hoover, Arambula, Calderon, Caloza, Dixon, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta
ABS, ABST OR NV: Tangipa
UPDATED
VERSION: August 20, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0003895
SENATE THIRD READING
STR Bill Id:SB 1089
Author:(Richardson)
As Amended Ver:June 18, 2026
Majority vote
SUMMARY
Expands California Health and Human Services Agency (CalHHS) authority under CalRx to enter into partnerships for glucagon-like peptide-1 (GLP-1) medications.
Major Provisions
- Specifies that a GLP-1 approved by the U.S. Food and Drug Administration (FDA) includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide;
- Requires CalHHS make its best effort to negotiate pricing at or lower than the 2025 cost to Medi-Cal beneficiaries; and,
- Makes findings and declarations related to chronic weight disease.
COMMENTS
Obesity is a chronic health condition characterized by an increase in the size and amount of fat cells in the body. Health care providers screen for obesity by calculating patients' body mass index (BMI), which takes into account an individual's height and weight. Adults with a BMI of 25 to <30 are categorized as overweight and those with a BMI of 30 or higher are categorized as obese. There are many health consequences of obesity such as an increased risk of heart disease, diabetes, respiratory issues, musculoskeletal disorders, and certain cancers, as well as reduced life expectancy. Causes of obesity are multi-faceted and can include lifestyle habits, environment, stress, health conditions and certain medications, socioeconomic factors, and individual characteristics such as genetics and metabolism. Overall, it is estimated that 15.2% of adolescents aged 12 to 17 years and 27.8% of adults aged 18 to 64 years with private health insurance in California have BMIs that categorize them as having obesity.
Recent elimination of GLP-1 coverage in Medi-Cal. California's Medi-Cal program had previously opted to cover GLP-1 medications with an FDA indication for weight management, with quantity limits and labeler restrictions. However, this coverage was eliminated as of December 31, 2025. In 2024, the state reimbursed more than $1.6 billion for two GLP-1 drugs, representing approximately 10% of Medi-Cal's total pharmacy spending. Coverage for GLP-1 medications for Medi-Cal beneficiaries with other FDA-approved indications for GLP-1 medications (e.g., diabetes) remains intact.
CalRx. To help reduce the cost of prescription drugs in state programs and to consumers, the state recently created the CalRx program at the Department of Health Care Access and Information (HCAI). Established by SB 852 (Pan), Chapter 207, Statutes of 2020, the program aims to reduce the cost of drugs by expanding the availability of low‑cost generics in the market. According to the Legislative Analyst's Office (LAO), CalRx accomplishes this objective by entering into partnerships with private entities to distribute or manufacture generic drugs. Before entering into these partnerships, HCAI must ensure they result in savings, address market failures, improve patient access, and are viable. The Legislature has directed HCAI to work on two key drug initiatives through CalRx, insulin and naloxone. CalRx has executed contracts for both drugs, offering an over‑the‑counter naloxone nasal spray product at $24 for each twin pack and a biosimilar insulin pen at $55 for a five-pack of 3mL pens.
According to the Author
Chronic weight disease is a serious problem in the United States. The author states that there are approximately 24.5 million adults between the ages of 18-64 years living in California. The author continues that according to UCLA's California Health Interview Survey, nearly 61% of California adults fall into the combined overweight/obese category, which is associated with 200 morbid conditions, including 13 types of cancer. The author states that chronic weight management can be related to a reduced labor participation, earnings, increased early mortality, absenteeism, disability, and healthcare costs exceeding $1 billion and a 2.6% reduction in the California Gross Domestic Product.
Arguments in Support
California Life Sciences (CLS) supports this bill, stating that it is an important step toward ensuring that the transformative GLP-1 therapies California's biopharmaceutical industry has helped develop can reach the patients who need them most. CLS continues that the development of GLP-1 receptor agonists and related therapies represents one of the most significant breakthroughs in metabolic medicine in decades, yet cost and access remain the primary barriers preventing Californians from benefiting from these innovations. CLS states that this bill ensures that FDA approval and clinical validation translate into real patient access, fulfilling the promise of the regulatory pathway and supporting the commercial viability of treatments that required enormous scientific and financial investment to bring to market. CLS continues that it positions California as a state where breakthrough therapies reach patients equitably — reinforcing the case for continued innovation investment in metabolic and preventive medicine and signaling to the broader industry that California rewards scientific progress with meaningful policy.
Arguments in Opposition
None to the current version of the bill.
FISCAL COMMENTS
According to the Assembly Committee on Appropriations, HCAI estimates one-time costs of several million dollars to establish partnerships for development, distribution, or procurement of a GLP-1 and ongoing costs, likely several thousand dollars per year, for two staff positions (General Fund). Eventually, sales of the drug should cover the costs of manufacturing or contracting.
VOTES
SENATE FLOOR: 39-0-1
YES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Cervantes, Choi, Cortese, Durazo, Gonzalez, Grayson, Grove, Hurtado, Jones, Laird, Limón, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Reyes, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
ABS, ABST OR NV: Dahle
ASM HEALTH: 15-0-1
YES: Bonta, Chen, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Mark González, Patel, Patterson, Celeste Rodriguez, Sanchez, Schiavo, Sharp-Collins, Stefani
ABS, ABST OR NV: Johnson
ASM APPROPRIATIONS: 14-0-1
YES: Wicks, Hoover, Arambula, Calderon, Caloza, Dixon, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta
ABS, ABST OR NV: Tangipa
UPDATED
VERSION: June 18, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0003587
Date of Hearing: August 5, 2026
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
SBPCA Bill Id:SB 1089
Author:(Richardson) – As Amended Ver:June 18, 2026
Policy Committee: | Health | Vote: | 15 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill adds a glucagon-like peptide-1 (GLP-1) antiobesity medication to the California Health and Human Services Agency’s (CalHHS) authority to enter partnerships for generic or brand name drugs to address emerging health concerns.
Specifically, this bill:
- Specifies that a GLP-1 approved by the U.S. Food and Drug Administration (FDA) includes a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide.
- Requires CalHHS make its best effort to negotiate pricing at or lower than the 2025 cost to Medi-Cal beneficiaries.
- Makes findings and declarations related to chronic weight disease.
FISCAL EFFECT:
The Department of Health Care Access and Information (HCAI) estimates one-time costs of several million dollars to establish partnerships for development, distribution, or procurement of a GLP-1 and ongoing costs, likely several thousand dollars per year, for two staff positions (General Fund). Eventually, sales of the drug should cover the costs of manufacturing or contracting.
COMMENTS:
- Purpose. According to the author:
Chronic weight disease is a serious problem in the United States. According to UCLA’S California Health Interview Survey, nearly 61% of California adults fall into the combined overweight/obese category, which is associated with 200 morbid conditions, including 13 types of cancer.
Chronic weight management can be related to reduced labor market participation, earnings, increased early mortality, absenteeism, disability and healthcare costs exceeding $1 billion and a 2.6% reduction in the California Gross Domestic Product.
- Background. Obesity and Overweight. Obesity is a chronic health condition characterized by an increase in the size and number of fat cells in the body. Body mass index (BMI), which takes into account an individual’s height and weight, is a measurement used to identify obesity. Adults with a BMI of 25 to <30 are categorized as overweight and those with a BMI of 30 or higher are categorized as obese. Obesity has many health consequences, including risk of heart disease, diabetes, respiratory issues, musculoskeletal disorders, certain cancers, and reduced life expectancy. Barriers to accessing treatment for obesity include stigma, race and ethnicity, location, and cost.
CalRx. To reduce the cost of prescription drugs in state programs and for consumers, the state enacted SB 852 (Pan), Chapter 207, Statutes of 2020, creating the CalRx program within HCAI. CalRX aims to expand the availability of low-cost generics in the market by entering partnerships with private entities to distribute or manufacture generic drugs. Before entering such partnerships, HCAI must determine they are viable, will result in savings, address market failures, and improve patient access. CalRx has executed contracts and now offers an over-the-counter naloxone nasal spray product at $19 per twin-pack and a biosimilar insulin pen at $55 for a five-pack of 3mL pens. HCAI reports CalRx naloxone was cost-saving only a few months into launch, and expects CalRx insulin to be cost-saving after a longer period on the market.
Recent Elimination of GLP-1 Coverage for Weight Loss in Medi-Cal. California’s Medi-Cal program had previously covered GLP-1 medications with an FDA indication for weight management, with restrictions. However, this coverage was eliminated as of December 31, 2025. In 2024, the state reimbursed more than $1.6 billion for two GLP-1 drugs, representing approximately 10% of Medi-Cal's total pharmacy spending. Medi-Cal continues to cover GLP-1 medications for Medi-Cal beneficiaries with other FDA-approved indications for GLP-1 medications, including type-2 diabetes.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: June 16, 2026
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
SBPCA Bill Id:SB 1089
Author:(Richardson) – As Amended Ver:May 14, 2026
SENATE VOTE: 39-0
SUBJECT: Preventive Treatment Health Care Act.
SUMMARY: Requires a health benefit plan or contract offered to public employees and annuitants to offer coverage for chronic weight disease management or to treat obesity or overweight persons, including nutritional information and at least one glucagon-like peptide-1 (GLP-1) approved by the United States Food and Drug Administration (FDA). Expands California Health and Human Services Agency (CHHSA) authority under CalRx to enter into partnerships for GLP-1s. Specifically, this bill:
- Requires a health benefit plan or contract that contract with the California Public Employee’s Retirement System (CalPERS) board to offer coverage for chronic weight disease management or to treat obesity or overweight persons, including nutritional information and at least one GLP-1 antiobesity medication approved by the FDA.
- Permits, when determining the cost for weight disease management or treatments for obesity or overweigh persons, the cost to Medi-Cal beneficiaries in the year 2025 or better pricing to be considered.
- Sunsets 1) and 2) above on January 1, 2032.
- Expands CHHSA authority under CalRx, subject to appropriation by the Legislature, to enter into partnerships to increase competition, lower prices, and address supply shortages for at least one GLP-1 antiobesity medication approved by the FDA. Requires CHHSA to make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
- Defines GLP-1 antiobesity medication approved by the FDA to include a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide.
- Makes legislative findings and declarations about chronic weight disease and associated conditions and health outcomes.
EXISTING LAW:
- Establishes the CHHSA, which consists of the following departments and offices: Aging, Child Support Services, Community Services and Development, Developmental Services, Health Care Access and Information (HCAI), Health Care Services, Managed Health Care (DMHC), Public Health, Rehabilitation, Social Services, State Hospitals, the Center for Data Insights and Innovation, the Emergency Medical Services Authority, the Office of Technology and Solutions Integration, the Office of Law Enforcement Support, the Office of the Surgeon General, the Office of Youth and Community Restoration, and the State Council on Developmental Disabilities. [Government Code (GOV) § 12803 and § 12806]
- Establishes the California Affordable Drug Manufacturing Act of 2020. Requires CHHSA or its departments to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. Permits CHHSA and its departments to enter into exclusive or nonexclusive contracts on a bid or negotiated basis. [Health and Safety Code (HSC) § 127690, et seq.]
- Requires CHHSA to enter into partnerships resulting in the production, procurement, or distribution of generic prescription drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. States that CHHSA will only enter into production partnerships at a price that results in savings, targets failures in the market for generic drugs, or improves patient access to affordable medications. Requires CHHSA to prioritize the selection of generic prescription drugs that have the greatest impact on lowering drug costs to patients, increasing competition and addressing shortages in the prescription drug market, improving public health, or reducing the cost of prescription drugs to public and private purchasers. [HSC § 127693]
- Permits CHHSA and its departments, including HCAI, to enter into exclusive or nonexclusive contracts on a bid or negotiated basis in accomplishing 2) above. Exempts contracts entered into or amended pursuant to this authority from 7) and 8) of existing law below, and exempts these contracts from the review or approval of any division of the Department of General Services (DGS). [HSC § 127692]
- Permits CalRx, subject to appropriation, to enter into partnerships to increase competition, lower prices, and address supply shortages for: over-the-counter naloxone products; generic or brand name drugs to address emerging health concerns, including reproductive health care or gender affirming health care; development, production, procurement, or distribution of vaccines, as specified; and, the manufacture, purchase, or distribution of medical supplies or medication devices. [HSC § 127697]
- Establishes the Public Employees’ Medical and Hospital Care Act and the Board of Administration of CalPERS to provide health care, retirement, and other benefits to state and other government employees and retirees. [GOV §§ 22750-22755]
- Requires a health benefit plan or contract to provide coverage for an FDA-approved vaccine for AIDS, contraceptives and related services, and vasectomies and related services, consistent with laws that apply to health plans regulated by DMHC and insurers regulated by the California Department of Insurance (CDI). [GOV § 22853.1, § 22853.3, and § 22853.4]
FISCAL EFFECT: According to the Senate Committee on Appropriations, unknown significant General Fund costs, at least tens of millions annually until January 1, 2032, due to increases in CalPERS plan premiums. HCAI estimates General Fund costs of approximately $450,000 for staffing resources to enter into partnerships (this assumes CHHSA would delegate these responsibilities to HCAI). In addition, HCAI estimates General Fund costs of several million dollars to effectuate partnerships for development, distribution, or procurement.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, chronic weight disease is a serious problem in the United States. The author states that there are approximately 24.5 million adults between the ages of 18-64 years living in California. The author continues that according to UCLA’s California Health Interview Survey, nearly 61% of California adults fall into the combined overweight/obese category, which is associated with 200 morbid conditions, including 13 types of cancer. The author states that chronic weight management can be related to a reduced labor participation, earnings, increased early mortality, absenteeism, disability, and healthcare costs exceeding $1 billion and a 2.6% reduction in the California Gross Domestic Product. The author notes that CalPERS health insurance covers more than 1.5 million public employees. The author continues that as the largest purchaser of public employee health benefits in California, the program provides coverage for over 1,200 public agencies and schools. The author concludes that this bill will require CalPERS to offer GLP-1s as an optional benefit through their health plan to reduce chronic weight management and reduce overall employer costs.
- BACKGROUND. Obesity is a chronic health condition characterized by an increase in the size and amount of fat cells in the body. Health care providers screen for obesity by calculating patients’ body mass index (BMI), which takes into account an individual’s height and weight. Adults with a BMI of 25 to <30 are categorized as overweight and those with a BMI of 30 or higher are categorized as obese. There are many health consequences of obesity such as an increased risk of heart disease, diabetes, respiratory issues, musculoskeletal disorders, and certain cancers, as well as reduced life expectancy. Causes of obesity are multi-faceted and can include lifestyle habits, environment, stress, health conditions and certain medications, socioeconomic factors, and individual characteristics such as genetics and metabolism. Overall, it is estimated that 15.2% of adolescents aged 12 to 17 years and 27.8% of adults aged 18 to 64 years with private health insurance in California have BMIs that categorize them as having obesity. According to CalPERS, within their Basic and Medicare population of approximately 1,282,000 members, an estimated 360,000 (28%) have obesity or severe obesity and an additional 240,000 (19%) are overweight, together representing more than 600,000 potentially eligible members, or nearly half the Basic and Medicare population.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits (EHBs), and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Baseline coverage. CHBRP estimates that at baseline, 187,000 CalPERS enrollees (15.3%) with state-regulated insurance subject to the mandate are enrolled in a plan that covers GLP-1 medications for weight management – specifically, Blue Shield HMO, which added this coverage as of January 1, 2026. The remaining 1,037,000 enrollees (84.7%) are in plans that do not cover GLP-1 medications for weight management.
- Medical effectiveness. CHBRP found that there is very strong evidence for adults and strong evidence for children and adolescents that GLP-1s result in weight loss.
- Public health impacts. CHBRP found that enrollees newly using GLP-1s would experience an average of 4.8% to 17.8% reduction in body weight and improvements in related health improvements over time. However, because this bill would not impact coverage for commercial or Medi-Cal enrollees, CHBRP found that this bill could exacerbate existing disparities in obesity and treatment.
- Long-term impacts. CHBRP found that over time, utilization of GLP-1s among CalPERS enrollees would increase and therefore premium impacts would increase in the long term. Cost offsets from reduced obesity-related medical expenditures (cardiovascular events, diabetes management, kidney disease, joint replacement) are expected to grow over time as enrollees maintain therapy. Competition from new entrants, biosimilars, and evolving pricing of GLP-1s may also affect long-term unit costs.
- Premium and enrollee impacts. At the time of the publication of this analysis, CHBRP’s estimated premium impacts are outdated due to amendments taken in the Senate. However, CalPERS recently released an analysis of the current version of this bill with projected premium impacts, covered in the paragraph below.
- CalPERS premium impact. According to an analysis of this bill published for their upcoming June 17 board meeting, CalPERS estimates that in the first-year premiums would increase by increase $437.3 million, or $28.09 per member per month (PMPM), with costs expected to grow by tens of millions of dollars annually in subsequent years as utilization rises. The state’s General Fund share is estimated to be $187.2 million ($30.33 PMPM) in year one. CalPERS notes that these figures likely underestimate the true fiscal impact, as they do not account for the loss of CalPERS’ negotiating leverage or the costs of managing side effects. CalPERS notes that CHBRP’s analysis projected medical costs savings of approximately $454 per GLP-1 medication user annually after five or more years. However, this will only offset a fraction of the cost of the drugs. CalPERS states that these findings highlight the significant cost impact associated with GLP-1 coverage, with all members experiencing a higher premium, while projected long-term medical savings remain comparatively minimal.
- Recent elimination of GLP-1 coverage in Medi-Cal. California’s Medi-Cal program had previously opted to cover GLP-1 medications with an FDA indication for weight management, with quantity limits and labeler restrictions. However, this coverage was eliminated as of December 31, 2025. In 2024, the state reimbursed more than $1.6 billion for two GLP-1 drugs, representing approximately 10% of Medi-Cal's total pharmacy spending. Coverage for GLP-1 medications for Medi-Cal beneficiaries with other FDA-approved indications for GLP-1 medications (e.g., diabetes) remains intact.
- Growing consumer premiums and affordability concerns. Over the last two decades, significant federal policy changes have reshaped the health insurance landscape in California, expanding coverage, increasing affordability, and strengthening consumer protections for millions of residents. These policies drove historic reductions in the uninsured rate and provided greater stability for families, providers, and health systems across the state. These gains, however, are under threat as the expiration and rollback of key federal supports, combined with broader economic uncertainty and rising health care costs, risk reversing hard-won progress and increasing the number of Californians who are struggling to access affordable health care. According to the California Health Care Foundation 2026 Health Policy Survey (CHCF Survey), half of Californians (51%) reported that their health care expenses have increased faster than their incomes, and a vast majority (71%) are experiencing financial strain due to health care costs. About 6 in 10 Californians overall (59%), and 70% of Californians with low incomes, say they skipped or postponed care due to cost in the past year. Nearly half of Californians (47%) say it is “very” or “somewhat” difficult to afford health care.
- Employer coverage. For those on employer-based individual and family plans, the California Health Benefits Survey found that the average total premium for family coverage in California has increased by 24% since 2022 – rapidly outpacing the national rates of inflation (12%) and wages (14%). This continues a 20-year trend: according to the UC Labor Center, family health care premiums for private-sector workers have grown by 129% since 2005, faster than the state’s median household income (94%) and the inflation rate (69%). Because health insurance is part of an employee’s total compensation plan, higher premiums cut into employee wage increases and other benefits.
- CalRx. To help reduce the cost of prescription drugs in state programs and to consumers, the state recently created the CalRx program at HCAI. Established by SB 852 (Pan), Chapter 207, Statutes of 2020, the program aims to reduce the cost of drugs by expanding the availability of low‑cost generics in the market. According to the Legislative Analyst’s Office (LAO), CalRx accomplishes this objective by entering into partnerships with private entities to distribute or manufacture generic drugs. Before entering into these partnerships, HCAI must ensure they result in savings, address market failures, improve patient access, and are viable. The Legislature has directed HCAI to work on two key drug initiatives through CalRx, insulin and naloxone. CalRx has executed contracts for both drugs, offering an over‑the‑counter naloxone nasal spray product at $24 for each twin pack and a biosimilar insulin pen at $55 for a five-pack of 3mL pens.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits (EHBs), and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- SUPPORT. California Life Sciences (CLS) supports this bill, stating that it is an important step toward ensuring that the transformative GLP-1 therapies California’s biopharmaceutical industry has helped develop can reach the patients who need them most. CLS continues that the development of GLP-1 receptor agonists and related therapies represents one of the most significant breakthroughs in metabolic medicine in decades, yet cost and access remain the primary barriers preventing Californians from benefiting from these innovations. CLS argues that this bill closes this access gap by mandating coverage for evidence-based chronic weight disease management within the CalPERS system, with pricing benchmarked to 2025 Medi-Cal rates or better. CLS notes that for life sciences companies, this is consequential in two ways. First, CLS states that it ensures that FDA approval and clinical validation translate into real patient access, fulfilling the promise of the regulatory pathway and supporting the commercial viability of treatments that required enormous scientific and financial investment to bring to market. Second, CLS continues that it positions California as a state where breakthrough therapies reach patients equitably — reinforcing the case for continued innovation investment in metabolic and preventive medicine and signaling to the broader industry that California rewards scientific progress with meaningful policy.
- PREVIOUS LEGISLATION.
- AB 575 (Arambula) of 2025 would have required an individual or group health plan contract or health insurance policy that provides coverage for outpatient prescription drug benefits to include coverage for at least one FDA-approved GLP-1 receptor agonist and intensive behavioral therapy for the treatment of obesity without prior authorization. AB 575 was held in the Assembly Health Committee.
- SB 535 (Richardson) of 2025 would have required health plans and health insurers that provide coverage for outpatient prescription drug benefits to include coverage intensive behavioral therapy, bariatric surgery, and at least one FDA-approved anti-obesity medication.
- SB 1008 (Bradford) of 2024 was substantially similar to SB 535 (Richardson). SB 1008 was held in the Senate Appropriations Committee.
- SB 839 (Bradford) of 2023 was substantially similar to AB 575, except that SB 839 did not prohibit prior authorization and prohibited cost-sharing from being different or separate from other illnesses, conditions, or disorders. SB 839 was not heard in the Senate Health Committee at the author’s request.
- AB 116 (Committee on Budget), Chapter 21, Statutes of 2025, expands authority for CalRx to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns including reproductive health care, gender affirming health care, vaccines, medical supplies, and medical devices.
- AB 118 (Committee on Budget), Chapter 42, Statutes of 2023, clarifies and provides additional flexibility for CalRx to procure various pharmaceutical drugs in addition to its existing efforts to manufacture generic forms of insulin.
- SB 184 (Committee on Budget and Fiscal Review), Chapter 47, Statutes of 2022, permits, until December 31, 2027, CHHSA and its departments to enter into contracts on a bid or negotiated basis and exempts these contracts from review or approval by the DGS for purposes of implementing CalRx.
- SB 154 (Skinner), Chapter 43, Statutes of 2022, known as the Budget Act of 2022, appropriated $100 million to support the development of three low-cost biosimilar insulin products and a California-based insulin manufacturing facility, and required expenditures for construction or acquisition of the facility to result in full or partial ownership of the facility by the state.
- SB 838 (Pan), Chapter 603, Statutes of 2022, requires CalRx to enter into a partnership to manufacture at least one form of insulin, to be made available at production and dispensing costs; requires this partnership to include representation and involvement with the governance of the contractor entity; and, requires CalRx, upon appropriation by the Legislature, to develop a California-based manufacturing facility for generic drugs, as specified.
- SB 852 (Pan) Chapter 207, Statutes of 2020, establishes CalRx.
- DOUBLE REFERRAL. This bill is double referred. Should this bill pass out of this committee, it will be referred to the Assembly Committee on Public Employment and Retirement.
- POLICY COMMENTS.
- Exacerbating existing disparities. Obesity rates are lowest among those with the highest incomes and educational attainment. Rates of obesity vary in California by race and ethnicity, with Asian adults reporting the lowest rates of obesity (11.1%), followed by white adults (24.8%), Black adults (37.1%), Latino adults (39.4%), and American Indian/Alaska Native adults (45.6%). CHBRP notes that in addition to disparities in obesity rates by race and ethnicity, there are also disparities in use of anti-obesity medications. Specifically, it was found that Black and Latino adults with obesity were more likely to have financial barriers to accessing GLP-1 medications and were less likely to receive prescriptions compared to white adults. CHBRP notes that research also shows that the high cost of some obesity treatments, including GLP-1 medications, makes them inaccessible for patients with lower incomes.
This bill only expands GLP-1 coverage for CalPERS enrollees but would not provide coverage for enrollees of Medi-Cal, commercial CDI-regulated policies and commercial (non-CalPERS) DMHC-regulated plans. Therefore, this bill would contribute to increasing disparities coverage for GLP-1 medications for weight management and could further exacerbate racial and socioeconomic disparities in obesity rates overall. The Legislature must weigh if prioritizing GLP-1 coverage for public employees is worth the risk of increasing health access and outcome disparities, especially just one year after such coverage was eliminated for the lowest-income Californians under Medi-Cal.
- Priorities in the midst of an affordability crisis. As detailed in the background section of this analysis, health insurance premiums are skyrocketing due to federal policy changes and disinvestments. These increasing costs are putting immense pressure on the pockets of millions of Californians and pushing many to abandon coverage altogether. This committee has held two informational hearings on this topic this year where firsthand stories of these impacts were shared. For example, a retired veteran from Colusa County testified about premiums for himself and his wife jumping from $540 a month to nearly $4,000 a month from 2025 to 2026. A cost that is more than double his monthly mortgage, and one he simply cannot afford on his fixed income. Stories like this represent the current reality for millions of people across the state, and public employees aren’t exempt from these affordability pressures. In their analysis of this bill, CalPERS cautions that the cost of expanding GLP-1 coverage will directly impact members in the form of higher premiums. For retirees on fixed incomes, higher premiums may reduce financial stability. For active employees, higher premiums reduce take-home pay and increase pressure on wages and employer contributions, with broader implications for the state budget. This Legislature must thoroughly consider the impact of policies, such as those under this bill, that will significantly impact premiums at a time when there isn’t room for consumers to bear more monthly costs.
- PROPOSED AMENDMENTS. To address the concerns detailed above, the committee may wish to strike the CalPERS provisions of this bill and maintain the language expanding CalRx’s authority to enter into partnerships to lower costs for GLP-1s. This will give the state the opportunity to make meaningful progress to reduce the cost of these drugs without increasing health care costs for consumers.
REGISTERED SUPPORT / OPPOSITION:
Support
American Diabetes Association
California Academy of Family Physicians
California Life Sciences Association
California Orthopedic Association
California Rheumatology Alliance
CPCA Advocates, Subsidiary of the California Primary Care Association
Los Angeles County Medical Association
Los Angeles LGBT Center
Opposition
None on file
Analysis Prepared by: Riana King / HEALTH / (916) 319-2097
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | SB 1089 |
THIRD READING
Bill No: SB 1089
Author: Richardson (D)
Amended: 5/14/26
Vote: 21
SENATE HEALTH COMMITTEE: 10-0, 4/15/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Menjivar, Padilla, Rubio, Smallwood-Cuevas
NO VOTE RECORDED: Pérez
SENATE LABOR, PUB. EMP. & RET. COMMITTEE: 5-0, 4/22/26
AYES: Smallwood-Cuevas, Strickland, Cortese, Durazo, Laird
SENATE APPROPRIATIONS COMMITTEE: 7-0, 5/14/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
SUBJECT: Preventive Treatment Health Care Act
SOURCE: Author
DIGEST:
This bill requires a health benefit plan contract with the California Public Employees’ Retirement System (CalPERS) to offer coverage for chronic weight disease management or to treat obesity or overweight persons, including nutritional information and at least one glucagon-like peptide-1 (GLP-1) weight medication approved by the federal U.S. Food and Drug Administration (FDA). Sunsets the CalPERS provisions on January 1, 2032. Adds at least one GLP-1 antiobesity weight medication to existing authority granted to the California Health and Human Services Agency regarding CalRx.
ANALYSIS:
Existing law:
- Establishes the California Health and Human Services Agency (CHHSA), which consists of the following departments and offices: Aging, Child Support Services, Community Services and Development, Developmental Services, Health Care Access and Information (HCAI), Health Care Services, Managed Health Care (DMHC), Public Health, Rehabilitation, Social Services, State Hospitals, the Center for Data Insights and Innovation, the Emergency Medical Services Authority, the Office of Technology and Solutions Integration, the Office of Law Enforcement Support, the Office of the Surgeon General, the Office of Youth and Community Restoration, and the State Council on Developmental Disabilities. [Government Code (GOV) §12803 and §12806]
- Requires CHHSA or its departments, under the California Affordable Drug Manufacturing Act of 2020, to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs, as specified, and to increase patient access to affordable drugs. This program is referred to as CalRx. [Health and Safety Code (HSC) §127692(a)]
- Requires CalRx to enter into partnerships resulting in the production, procurement or distribution of generic drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Requires the generic drugs to be produced or distributed by a drug company or generic drug manufacturer that is registered with the FDA. Requires CalRx to only enter into partnerships to produce generic drugs at a price that results in savings, targets failures in the market for generic drugs, and improves patient access to affordable medications. [HSC §127693(a) and §127693(b)]
- Requires, in identifying generic prescription drugs to be produced, CHHSA to consider reports on prescription drug costs published by DMHC and the Department of Insurance (CDI), and pharmacy spending data from Medi-Cal and other entities for which the state pays the cost of generic prescription drugs. Requires the partnerships to include the production of at least one form of insulin, provided that a viable pathway for manufacturing a more affordable form of insulin exists. [HSC §127693(c)(1) and (2)]
- Authorizes CalRx, subject to appropriation, to enter into partnerships to increase competition, lower prices, and address supply shortages for: over-the-counter naloxone products; generic or brand name drugs to address emerging health concerns, including reproductive health care or gender affirming health care; development, production, procurement, or distribution of vaccines, as specified; and, the manufacture, purchase, or distribution of medical supplies or medication devices. [HSC §127697]
- Establishes the Public Employees’ Medical and Hospital Care Act and the Board of Administration of the CalPERS to provide health care, retirement, and other benefits to state and other government employees and retirees. [GOV §22750-§22755]
- Requires a health benefit plan or contract to provide coverage for an FDA-approved vaccine for AIDS, contraceptives and related services, and vasectomies and related services, consistent with laws that apply to health plans regulated by DMHC and insurers regulated by CDI. [GOV §22853.1, §22853.3, and 22853.4]
This bill:
- States intent to increase access to affordable glucagoin-like-peptide-1 (GLP-1) weight management medications in California.
- Requires, commencing January 1, 2028, a health benefit plan or contract that contracts with CalPERS to offer coverage for chronic weight disease management or to treat obesity or overweight persons, including nutritional information and at least one GLP-1 antiobesity medication approved by the U.S. FDA.
- Authorizes, when determining the cost for weight disease management or treatments for obesity or overweight persons, the cost to Medi-Cal beneficiaries in the year 2025, or better pricing to be considered.
- Requires chronic weight disease management or treatments for obesity or overweight persons as described above to follow indications for use in the label approved by the U.S. FDA.
- Sunsets 2) through 4) above on January 1, 2032.
- Authorizes CalRx to include at least one GLP-1 antiobesity medication approved by the U.S.FDA and requires the CHHSA to make its best effort to negotiate pricing at or lower than the cost to Medi-Cal beneficiaries in 2025.
- Defines GLP-1 antiobesity medication approved by the U.S. FDA to include a GLP-1, GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide plus GLP-1, GLP-1 receptor dual agonist, or tirzepatide.
Comments According to the author of this bill:
Chronic weight disease is a serious problem in the United States. There are approximately 24.5 million adults between the ages of 18-64 years living in California. According to UCLA’s California Health Interview Survey, nearly 61% of California adults fall into the combined overweight/obese category, which is associated with 200 morbid conditions, including 13 types of cancer. Chronic weight management can be related to reduced labor participation and earnings, increased early mortality, absenteeism, disability and healthcare costs exceeding $1 billion and a 2.6% reduction in the California Gross Domestic Product. CalPERS health insurance covers more than 1.5 million public employees. As the largest purchaser of public employee health benefits in California, the program provides coverage for over 1,200 public agencies and schools. This bill will require CalPERS to offer GLP-1s as an optional benefit through their health plan to reduce chronic weight management and reduce overall employer costs. Federal Executive Order authorized the Most-Favored-Nation Prescription Drug Pricing. This included offering GLP-1 medications at negotiated rate of $149 - $350 per month. These lower prices will be available through the Trump Rx platform. With CalRx offering affordable cost of $245 per month, 20% of California adults will reduce costs and employees will be more productive creating workforce savings.
Background
The Medicaid Drug Rebate Program provides a rebate to states for a portion of the Medicaid payment for each drug. The rebate is shared with the federal government. In return most manufacturer’s drugs are covered under state Medicaid programs. Some drugs or classes of drugs may be excluded from coverage, including drugs for weight loss. As of January 2026, 13 states covered GLP-1s for obesity treatment under Medicaid. Beginning in 2022, California consolidated pharmacy benefits under one system called Medi-Cal Rx, where the state pays for all drug claims on a fee-for-service basis, including for people in Medi-Cal managed care plans. Because of significant growth in the state’s pharmacy spending including for GLP-1 Agonists, in October 2025 pursuant to the enacted 2025-26 California state budget, Medi-Cal Rx announced that it will continue to cover GLP-1 medication when used for indications approved by the FDA, such as treating type 2 diabetes, atherosclerotic cardiovascular disease, and chronic kidney disease. Three drugs for weight loss or weight-loss indications would no longer be covered effective January 1, 2026. Coverage would continue for certain FDA-approved indications and for people younger than 21 years of age pursuant to the federal Early and Periodic Screening, Diagnostic, and Treatment benefit. The Budget Act of 2025 included General Fund savings of $85 million, increasing to $680 million annually by 2028-29 from the elimination of Medi-Cal coverage of GLP-1 drugs.
CalRx program currently produces Insulin Glargine at $55 for a five-pack of 3mLpens and leverages the state’s purchasing power to buy naloxone at a reduced cost (twin pack of over-the-counter naloxone nasal spray for $19). CalRx also plans to launch a centralized ordering system to supply California schools with albuterol inhalers and single-use disposable spacers at no cost over a three-year period beginning this summer. At an April 9, 2026, Senate Budget Health and Human Services Subcommittee hearing HCAI’s director indicated that GLP-1 antiobesity medications are among the drugs CalRx is considering for future inclusion.
California Health Benefits Review Program (CHBRP) report. CHBRP assumes this bill will require the CalPERS Premium Preferred Provider Organization to cover the medications described in this bill (it is the only plan offered statewide) and that it will obtain the Most Favored Nation pricing. Key findings specific to the CalPERS requirements include:
- Overweight vs. Obese. Adults with body mass index (BMI) between 25 to 30 are categorized as overweight and those with a BMI of 30 or higher are categorized as obese. Total medical expenditures attributed to obesity in California are equal to $7.1 billion in 2025. This includes direct costs of public and private health expenditures and out-of-pocket costs.
- GLP-1s. Currently, there are four GLP-1 medications approved for chronic weight management, and they are all available as subcutaneous injections with varying recommendations of frequency of administration. Oral formulations are likely to be available in the near future.
- Medical effectiveness. There is very strong evidence that FDA-approved GLP-1 medications for chronic weight management are effective when used as adjuncts to usual care (which includes standard diet and activity and lifestyle recommendations) for adults. Use of these medications increases the amount of weight loss and percentage of body weight loss, and reduces BMI, compared to placebo or usual care alone. There is strong evidence that GLP-1s improve weight loss in children and adolescents. There is very strong evidence that, for adults, gastrointestinal adverse events such as nausea, vomiting, indigestion, loss of appetite, headaches, abdominal pain, constipation, and diarrhea were more commonly experienced by GLP-1 groups than control groups. One medication was also associated with higher rates of gallbladder-related and pancreatic adverse events. For children and adolescents, there is very strong evidence that gastrointestinal events such as nausea, vomiting, and diarrhea are common while serious events are rare.
- Utilization. Assuming an average weight loss of 11.3%, this would translate into an approximate decrease in lost productivity of 2,679 days per year or $324,000 to $649,000 per year. These savings would grow overtime.
- Public health. Enrollees newly using GLP-1s would experience an average of 4.8% to 17.8% reduction in body weight and improvements in related health improvements over time.
- Long-Term Impacts. Over time, utilization of GLP-1s among CalPERS enrollees would be expected to increase and therefore premium impacts would increase in the long term. Cost offsets from reduced obesity-related medical expenditures (cardiovascular events diabetes management, kidney disease, joint replacement) are expected to grow over time as enrollees maintain therapy. Competition from new entrants, biosimilars, and evolving pricing of GLP-1s may also affect long-term unit costs.
- Other states. As of March 2025, 16 states covered GLP-1 medications for weight loss under their state employee health plan. At least four states have terminated coverage due to the high costs associated with use of GLP-1 medications.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee there are unknown significant General Fund costs, at least tens of millions annually until January 1, 2032, due to increases in CalPERS plan premiums.
Unknown General Fund costs for HCAI, likely hundreds of thousands, for staffing resources to enter into partnerships (this assumes CHHSA would delegate these responsibilities to HCAI). In addition, unknown General Fund costs of several million dollars to effectuate partnerships for development, distribution, or procurement.
SUPPORT: (Verified 5/14/26)
American Diabetes Association
California Academy of Family Physicians
California Black Health Network
California Orthopedic Association
California Primary Care Association
One individual
OPPOSITION: (Verified 5/14/26)
One individual
ARGUMENTS IN SUPPORT: The American Diabetes Association (ADA) writes that GLP-1 and GLP-1RA medications have proven transformative in the management of type 2 diabetes and obesity, improving blood glucose control, reducing cardiovascular risk, and contributing to meaningful weight reduction, yet access to these medications remains severely limited for many Californians due to inconsistent insurance coverage. The ADA supports efforts that bring evidence-based, life-saving diabetes therapies within reach of all who need them—particularly those in low-income and working-class populations who face the greatest barriers to consistent care. The ADA indicates this bill aligns with their mission to prevent type 2 diabetes and to improve the lives of all people affected by it. California Primary Care Association (CPCA) Advocates write this bill is particularly important for community health centers and their patients. CPCA Advocates indicates the high cost of these drugs has placed them out of reach for many patients who are uninsured or underinsured. They write that this bill will help community health clinics provide more effective, evidence-based care.
ARGUMENTS IN OPPOSITION: An individual writing on behalf of the California Small Business Association writes to express opposition to “costly health care mandates that are threatening the sustainability of employer-sponsored health care coverage” and lists four bills including this bill.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
5/18/26 15:19:39
**** END ****
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
SB 1089 (Richardson) - Preventive Treatment Health Care Act
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
SB 1089 would require a health plan that contracts with CalPERS to offer coverage for chronic weight disease management, including nutritional information and at least one GLP-1 anti-obesity medication, as specified; and authorize the California Health and Human Services Agency to enter into partnerships for at least one GLP-1 anti-obesity medication, as specified.
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on May 14, 2026
Fiscal Impact:
- Unknown significant General Fund costs, at least tens of millions annually until January 1, 2032, due to increases in CalPERS plan premiums.
- Unknown General Fund costs for the Department of Health Care Access and Information (HCAI), likely hundreds of thousands, for staffing resources to enter into partnerships (this assumes the California Health and Human Services Agency would delegate these responsibilities to HCAI). In addition, unknown General Fund costs of several million dollars to effectuate partnerships for development, distribution, or procurement.
Author Amendments:
Specify that GLP-1 anti-obesity medication includes a GLP-1 receptor dual agonist, remove provisions related to most favored nation pricing, and revise the requirement that a health plan that contracts with CalPERS offer coverage “for chronic weight disease management” to instead require that a health plan that contracts with CalPERS offer coverage “for chronic weight disease management or to treat obesity or overweight persons.”
-- END --
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
SB 1089 (Richardson) - Preventive Treatment Health Care Act
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
SB 1089 would require a health plan that contracts with CalPERS to offer coverage for chronic weight disease management, including nutritional information and at least one GLP-1 anti-obesity medication, as specified; and authorize the California Health and Human Services Agency to enter into partnerships for at least one GLP-1 anti-obesity medication, as specified.
Fiscal Impact:
- Unknown significant General Fund costs, at least tens of millions annually until January 1, 2032, due to increases in CalPERS plan premiums.
- The Department of Health Care Access and Information (HCAI) estimates General Fund costs of approximately $450,000 for staffing resources to enter into partnerships (this assumes the California Health and Human Services Agency would delegate these responsibilities to HCAI). In addition, HCAI estimates General Fund costs of several million dollars to effectuate partnerships for development, distribution, or procurement.
Background:
Glucagon-Like Peptide-1 (GLP-1) Medications. According to the California Health Benefits Review Program (CHBRP), the treatment of obesity is multi-faceted and includes behavioral and lifestyle changes, as well as anti-obesity medications, and surgery if indicated. Anti-obesity medications can be broken into two types of drugs: GLP-1 medications, and non–GLP-1 medications. GLP-1 medications are a class of drugs that activate the body’s GLP-1 receptors. This activation triggers several downstream effects, including lowering glucose (sugar) levels within the bloodstream, reducing digestion rate, and increasing the sensation of fullness for longer. Non–GLP-1 medications treat obesity through a variety of different mechanisms, including blocking fat absorption and deposition, suppressing appetite, and increasing metabolism. As of April 2026, there are four GLP-1 medications approved for chronic weight management. CHBRP indicates that benefit coverage for GLP-1 medications for weight loss is limited for enrollees in commercial DMHC-regulated plans and CDI-regulated policies.
CalRx. Current law authorizes the California Health and Human Services Agency, subject to an appropriation by the Legislature, to enter into partnerships to increase competition, lower prices, and address supply shortages under any of the following circumstances:
- For over-the-counter naloxone products. Partnerships may allow the development, manufacturing, or distribution of over-the-counter naloxone products by an entity that is authorized to do so under federal or state law.
- For generic or brand name drugs to address emerging health concerns, including in reproductive health care or gender affirming health care.
- For the development, production, procurement, or distribution of vaccines, by an entity that is authorized to do so under federal or state law, with the intent that these vaccines be made widely available to public and private purchasers, providers, suppliers, and pharmacies.
- For the manufacture, purchase, or distribution of medical supplies or medical devices.
Proposed Law:
Specific provisions of the bill would:
- Require, commencing January 1, 2028, a health benefit plan or contract that contracts with CalPERS to offer coverage for chronic weight disease management, including nutritional information and at least one GLP-1 anti-obesity medication, as defined, approved by the United States Food and Drug Administration (FDA); require that chronic weight disease management must be offered at the cost previously provided to Medi-Cal beneficiaries in the year 2025 or the most favored nation pricing, as described, or better pricing; require chronic weight disease management to follow FDA label indications for usage; and sunset these provisions on January 1, 2032.
- Authorize the California Health and Human Services Agency to additionally enter into partnerships for at least one GLP-1 anti-obesity medication, as defined, approved by the FDA; and require the California Health and Human Services Agency to make its best effort to negotiate pricing at or lower than the most favored nation or Medi-Cal.
Staff Comments:
CalPERS estimates SB 1089 would increase CalPERS plan premiums, ranging from $199.6 million to $437.3 million, in year one; and that from years two through five, these costs would increase by tens of millions annually due to increased awareness and utilization.
The CHBRP analysis of SB 1089 (March 24, 2026 version) estimates the bill would result in an increase in CalPERS plan premiums of $35,273,000.
-- END --
SENATE COMMITTEE ON LABOR, PUBLIC EMPLOYMENT AND RETIREMENT
Senator Lola Smallwood-Cuevas, Chair
2025 - 2026 Regular
Bill No: SB 1089 Hearing Date: April 22, 2026
Author: | Richardson | ||
Version: | March 24, 2026 | ||
Urgency: | No | Fiscal: | Yes |
Consultant: | Glenn Miles | ||
SUBJECT: Preventive Treatment Health Care Act
KEY ISSUE
This bill requires, commencing January 1, 2027, a health benefit plan or contract that contracts with the California Public Employees’ Retirement System (CalPERS), to offer optional coverage for chronic weight disease management, including nutritional information and at least one Glucagon-like peptide-1 (GLP-1) anti-obesity medication (AOM) approved by the U.S. Food and Drug Administration (FDA).
ANALYSIS
Existing law:
- Establishes the Public Employees’ Medical and Hospital Care Act (PEMHCA) and tasks the CalPERS board of directors to contract with carriers for health benefit plans or approve health benefit plans offered by employee organizations, with the purpose of providing public employees with health plan benefits similar to those available in private industry and promoting and preserving public employee health. (Government Code § 22750 et seq.)
- Requires a health benefit plan or contract to provide coverage for an FDA-approved vaccine for AIDS, contraceptives and related services, and vasectomies and related services, consistent with laws that apply to health plans regulated by the California Department of Managed Health Care (DMHC) and insurers regulated by the California Department of Insurance (CDI). (Government Code § 22853.1, § 22853.3, and § 22853.4)
- Sets minimum standards for public employees’ health benefits plans; minimum standards for health carriers; and minimum scope and content of basic health benefits plans, as specified. (2 C.C.R. §§ 599.508 – 599.510).
- Provides state regulation of health plans, as defined, through DMHC’s licensing authority under the Knox-Keene Act and regulates health insurance policies, as defined, through the California Department of Insurance (CDI). (Health and Safety Code § 1340 et seq. and Insurance Code § 106 et seq.)
- Establishes the California Health and Human Services Agency (CHHSA) consisting of several departments and offices including DMHC, Health Care Access and Information (HCAI), and the Center for Data Insights and Innovation. (Government Code § 12803 and § 12806)
- Requires CHHSA or its departments, under the California Affordable Drug Manufacturing Act of 2020, to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs, as specified, and to increase patient access to affordable drugs. This program is referred to as CalRx. (Health and Safety Code § 127692(a))
- Requires CalRx to enter into partnerships resulting in the production, procurement or distribution of generic drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Requires the generic drugs to be produced or distributed by a drug company or generic drug manufacturer that is registered with the FDA. Requires CalRx to only enter into partnerships to produce generic drugs at a price that results in savings, targets failures in the market for generic drugs, and improves patient access to affordable medications. (Health and Safety Code § 127693(a) and § 127693(b))
- Requires, in identifying generic prescription drugs to be produced, CHHSA to consider reports on prescription drug costs published by DMHC and CDI, and pharmacy spending data from Medi-Cal and other entities for which the state pays the cost of generic prescription drugs. Requires the partnerships to include the production of at least one form of insulin, provided that a viable pathway for manufacturing a more affordable form of insulin exists. (Health and Safety Code § 127693(c)(1) and (2))
- Authorizes CalRx, subject to appropriation, to enter into partnerships to increase competition, lower prices, and address supply shortages for: over-the-counter naloxone products; generic or brand name drugs to address emerging health concerns, including reproductive health care or gender affirming health care; development, production, procurement, or distribution of vaccines, as specified; and, the manufacture, purchase, or distribution of medical supplies or medication devices. (Health and Safety Code HSC § 127697)
This bill:
- Establishes the Preventive Treatment Health Care Act to promote access to affordable AOM for Californians. [1]
- Makes legislative findings and declarations related to among other issues: the state of chronic weight disease in California and its contributing role in other serious diseases, including cancer and heart disease; its impact on employee productivity and economic contributions; and costs to the state exceeding $1 billion in disability and health care.
- Requires a health benefit plan or contract that contracts with CalPERS, commencing January 1, 2027, to offer optional coverage for chronic weight disease management, including nutritional information and at least one FDA-approved AOM as one if its health plan options.
- Requires CalPERS-contracted plans to offer AOM at the cost previously provided to Medi-Cal beneficiaries in 2025 or at the most favored nation pricing, as set forth in federal Executive Order No. 14297 on May 12, 2025, or better pricing.
- Requires the AOM to follow FDA label indications for usage.
- Requires the California Health and Human Services Agency (CHHSA) to do the following:
- Make AOM available to state and local government employers;
- Determine if the state shall make AOM available to all Californians, including enrollees and insureds of licensed health care service plan contracts and health insurance policies;
- Determine if such availability shall be at the cost previously provided to Medi-Cal beneficiaries in 2025 or at most favored nation pricing, as set forth in federal Executive Order No. 14297 on May 12, 2025, or better pricing.
- Expand its existing partnerships for the acquisition or production of specified medicines to include the acquisition of certain brand name prescription drugs including AOM and AOM related supplies. [2]
- Provides that the bill’s provisions related to CalPERS and CHHSA making AOM available, as specified, shall remain in effect only until January 1, 2032, and as of that date are repealed.
- Requires CalRx to do the following:
- Enter into partnerships resulting in the acquisition of brand name prescription drugs and requires CalRx to include the acquisition or production of pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products.
- Requires CalRx to consider the cost previously provided to Medi-Cal beneficiaries in 2025 or a lower cost, and the cost previously provided at the most favored nation pricing as set forth in a May 12, 2025, federal Executive Order, or better pricing.
- Requires any CalRx partnerships to consider guaranteeing access to supply of pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP-GLP-1 tirzepatide, and future chronic weight disease products, and creating a state brand of those same products. [3]
COMMENTS
1. Background
This bill, following Senate Health Committee amendments that are to be adopted in this committee (see FN 2 above and Section 6 below), seeks to promote access to life-altering AOMs by requiring CalPERS to offer AOMs as an option in at least one of its plans and by authorizing CalRx to include AOMs in those pharmaceuticals for which it can enter into specified partnerships to develop and offer medicines. Please see the Senate Health Committee’s April 15, 2026, Policy Analysis of this bill for information regarding its provisions related to CHSSA and CalRx.[4] Our analysis relates to the provisions applicable to CalPERS.
CalPERS’ Role in Providing Health Coverage
Pursuant to existing law, CalPERS negotiates with insurance carriers and health plans to purchase and administer healthcare benefits coverage for approximately 1.5 million public employees and retirees.[5] (The California Department of Human Resources (CalHR) negotiates for other benefits for state employees such as dental and eyewear coverage.) In addition to the state, approximately 1,149 public agencies contract with CalPERS for health coverage.
CalPERS provides health coverage to public employees through Health Maintenance Organizations (HMOs), Exclusive Provider Organizations (EPOs), Preferred Provider Organizations (PPOs), fully funded insurance plans, and self-insured plans. These different organizations fall within multiple, overlapping regulatory frameworks. DMHC (Knox-Keene) regulates CalPERS’ HMO and EPO plans. CDI regulates CalPERS’ fully insured PPO plans. Additionally, CalPERS has adopted regulations on its self-insured PPO plans that generally follow federal Employee Retirement Income Security Act (ERISA) practices. Lastly, CalPERS also sets minimum plan standards and minimum coverage benefits that generally exceed regulatory requirements.
CalPERS’ Core Beliefs
CalPERS adheres to board-established core beliefs as part of its mission and values. One of its core beliefs is Health Program Sustainability which states, “The sustainability of the Health Program is the foremost consideration when reviewing proposed changes to benefits, coverage areas, and costs.”[6] Another CalPERS core belief, Affordability, holds that, “Health premiums and out-of-pocket costs must be affordable and sustainable for members and employers.”[7]
CalPERS’ Negotiation and Rate Development Process
CalPERS determines health premiums annually through its rate development process by which it negotiates methodically with health carriers to achieve the most competitive premiums possible for CalPERS members and employers. It compares each plan’s premium proposal against actual cost and utilizations trends using data from CalPERS’ Health Care Decision Support System (data warehouse) to create baseline premium projections for each plan.[8]
In July 2025, CalPERS announced that the overall weighted premium rate for its health plan premiums would increase in calendar year 2026 by 8.21%, with Medicare plans (i.e., plans available to CalPERS retirees) set to see an average increase of 10.78%.[9]
CalPERS noted that “Pharmacy costs continue to drive rate changes across plans as utilization and unit costs increase, particularly with specialty and brand name drugs. For Medicare premiums, revenue changes from the Centers for Medicare and Medicaid Services (CMS) and increased utilization of medical services further impact costs for both Medicare Advantage and Medicare Supplemental plans.”[10]
Committee Concerns
- Increased State Employee and Retiree Health Costs
This bill may result in increased health care premiums for public employees and retirees. Retirees are particularly vulnerable and highly sensitive to increased premium costs since they live on fixed income. Public employees faced with increased health care premium costs are likely to increase wage demands or demands for higher employer premium contributions in collective bargaining. Such demands are likely to increase pressure on the General Fund to subsidize those increases.
CalPERS healthcare premiums are paid by contributions from both the employer and the employee. For state employees, the employer premium contribution is based on a formula that is driven in part by employee plan utilization. In short, the formula generally provides that the state cover 80% of the weighted average premium for active employees and 80% of the average additional premium for their family members (80/80 formula). Actual contributions are based on collective bargaining agreements. Health care inflation for existing health plan premiums already substantially exceeds the Consumer Price Index (CPI) upon which the state generally bases increases to employee compensation. Any premium increases attributable to this bill will likely exacerbate employee and retiree dissatisfaction with current compensation levels.
- SB 1089’s Timeline for Implementation Conflicts with CalPERS Plan Design and Rate Setting Process
CalPERS begins its plan design negotiations approximately one and a half years in advance of new plan implementation. SB 1089 requires CalPERS contracting health plans to offer optional AOM coverage commencing January 1, 2027. However, CalPERS is in the middle of its process to adopt 2027 premium rates for 2027 plan changes that were negotiated in September 2027. Amending the bill’s timeline to January 1, 2028, would avoid substantially disrupting existing plan and rate negotiations.
- SB 1089’s Optional and Singular Plan Option design conflicts with CalPERS Plan Design Process
SB 1089 requires a CalPERS-contracted plan to offer “optional coverage…as part of one of its health plan options.” However, this conflicts with how CalPERS negotiates with plans and insurers for the greatest coverage for the best price. CalPERS essentially designs its plans to offer substantially the same coverage to all its participants and bids its design “wish list” to health plans and insurers for costs proposals to cover those benefits. This economy-of-scale and standardization approach is what gives CalPERS its negotiating power with health plan carriers and makes cross-comparison plan analysis effective. Plan individualization and optionalization undermines CalPERS negotiating ability and could likely result in increased health premium and administrative costs. Moreover, the resulting optional plan would likely experience adverse selection, high costs, and utilization that would make it unaffordable to public employees.
2. Need for this bill?
According to the author:
“Chronic weight management can be related to a reduced labor participation, earnings, increased early mortality, absenteeism, disability and healthcare costs exceeding $1 Billion dollars and a 2.6% reduction in the California Gross Domestic Product (GDP). Barriers to the reduction, maintenance, or elimination of chronic weight disease come down to access and cost.”
“SB 1089 will create a five-year pilot program under CalPERS to require GLP-1 medications to be provided as part of CalPERS health plan. It would also add GLP-1 to the group of medications produced by CalRx.”
3. Proponent Arguments
According to the California Academy of Family Physicians (CAFP):
“CAFP views this bill as an important step in the right direction toward expanding access to chronic weight disease treatment. While we strongly support the bill’s focus on public employees and annuitants, we believe these policies should ultimately be extended to all Californians across all insurance markets. Limiting coverage to a subset of patients risks perpetuating inequities in access to effective treatment. Expanding coverage requirements to all health plans would promote more consistent, equitable care statewide.”
According to CPCA Advocates:
“SB 1089 is particularly important for community health centers and their patients. CHCs serve populations with disproportionately high rates of diabetes, obesity, and related chronic conditions. While newer treatments such as GLP-1 receptor agonists have shown significant clinical effectiveness, their high cost has placed them out of reach for many patients, especially those who are uninsured or underinsured.”
4. Opponent Arguments: None received.
5. Dual Referral: The Senate Rules Committee referred this bill to the Senate Health Committee (1) and the Senate Labor, Public Employment and Retirement Committee (2).
6. Senate Health Committee Amendments
The author agreed to accept amendments from the Senate Health Committee, which will be taken in the Senate Labor Public Employees and Retirement Committee (see FN 2) due to time and legislative calendar constraints related to hearing the bill in two committees so close together. Those amendments remove requirements on CHSSA, as specified, and leave the mandate on CalPERS health plans and the authorization for CalRx to include AOM in its partnership activities to source and/ or produce specified medicines.
7. Senate Labor, Public Employees and Retirement Committee Recommended Amendments:
To address some committee concerns outlined above, the committee recommends the following amendments:
- Delay implementation until January 1, 2028, to coincide with CalPERS’ regular plan design and rate determination process.
- Eliminate references to “optional coverage” of AOM and references to AOM coverage “as part of one of its health care options”.
SEC. 3. Section 22853.5 is added to the Government Code, to read:
22853.5. (a) Commencing January 1, 2027, January 1, 2028, a health benefit plan or contract that contracts with the board pursuant to this chapter shall offer optional coverage for chronic weight disease management, including nutritional information and at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration, as part of one of its health plan options.…
8. Prior Legislation:
SB 535 (Richardson, 2025) would have required health plans and health insurers that provide coverage for outpatient prescription drug benefits to include coverage for intensive behavioral therapy, bariatric surgery, and at least one FDA-approved anti-obesity medication. SB 535 was held on the Assembly Appropriations Suspense File.
SB 839 (Bradford, 2023) would have required an individual or group health plan contract or health insurance policy to include comprehensive coverage for the treatment of obesity, including coverage for intensive behavioral therapy, bariatric surgery, and FDA-approved AOM. This bill died in the Senate Health Committee.
SB 523 (Leyva, Chapter 630, Statutes of 2022) prohibits employment-related discrimination on the basis of reproductive health decision-making, and, beginning in 2024, modifies several aspects of the laws governing health benefits plans and health insurance policies in order to expand coverage, reduce costs, and lower barriers to reproductive health services, including requiring coverage for contraceptives and vasectomies.
SUPPORT
American Diabetes Association
California Academy of Family Physicians
California Black Health Network
California Orthopedic Association
CPCA Advocates, Subsidiary of the California Primary Care Association
OPPOSITION
None received
-- END --
The bill alternatively references chronic weight disease management, chronic weight disease management medications, Glucagon-like peptide-1 (GLP-1) anti-obesity medications, and anti-obesity medications throughout its provisions. We understand these references to generally mean the same thing, coverage for chronic weight disease management, including nutritional information and at least one Glucagon-like peptide-1 (GLP-1) anti-obesity medication. In this analysis, we opt to use the acronym AOM (anti-obesity medication) for all versions of these references. ↑
The author agreed to accept Senate Health Committee amendments to remove the bill’s provisions related to CHHSA. Due to time limitations to hear the bill in both committees, those amendments will be taken in Senate LPER Committee. ↑
The agreed upon Senate Health Committee amendments referenced in Footnote 2 (FN2) also revise the bill’s requirements on CalRx to instead provide that CalRx is authorized to include at least one AOM in the list of medications CalRx may, subject to an appropriation, enter into partnerships, as specified. ↑
CA Senate Committee on Health, SB 1089 Policy Bill Analysis https://leginfo.legislature.ca.gov/faces/billAnalysisClient.xhtml?bill_id=202520260SB1089 ↑
CalPERS Facts at a Glance, Calendar Year 2024 Health benefits Program (PDF) https://www.calpers.ca.gov/about/organization/facts-at-a-glance ↑
CalPERS Mission and Vision, CalPERS Beliefs, Health Benefits, Theme: Health Program Sustainability: https://www.calpers.ca.gov/about/organization/calpers-story/our-mission-vision ↑
Ibid., CalPERS Beliefs, Health Benefits, Theme: Affordability ↑
How CalPERS Sets Health Premiums, https://www.calpers.ca.gov/members/health-benefits/plans-and-rates/how-calpers-sets-health-premiums ↑
CalPERS News, “CalPERS Announces Health Plan Premiums for 2026”, July 15, 2025, https://www.calpers.ca.gov/newsroom/calpers-news/2025/calpers-announces-health-plan-premiums-for-2026 ↑
Ibid. ↑
SENATE COMMITTEE ON HEALTH
Senator Dr. Akilah Weber Pierson, Chair
BILL NO: SB 1089
AUTHOR: | Richardson | ||
VERSION: | March 24, 2026 | ||
HEARING DATE: | April 15, 2026 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Preventive Treatment Health Care Act
SUMMARY:
Requires the California Health and Human Services Agency to make a variety of glucagon-like peptide-1 (GLP-1) weight loss medications and future chronic weight disease products available to state and local government employers and determine if those medications should be made available to all Californians at the cost that Medi-Cal previously paid or federal most favored nation pricing. Requires a health benefit plan contract with the California Public Employees’ Retirement System to offer optional coverage for chronic weight disease management, including nutritional information and pens, vial injections, pills, and patches of a variety of GLP-1 weight loss medications and future chronic weight disease products, as part of one of its health plan options. Sunsets these provisions on January 1, 2032.
Existing law:
- Establishes the California Health and Human Services Agency (CHHSA), which consists of the following departments and offices: Aging, Child Support Services, Community Services and Development, Developmental Services, Health Care Access and Information (HCAI), Health Care Services, Managed Health Care (DMHC), Public Health, Rehabilitation, Social Services, State Hospitals, the Center for Data Insights and Innovation, the Emergency Medical Services Authority, the Office of Technology and Solutions Integration, the Office of Law Enforcement Support, the Office of the Surgeon General, the Office of Youth and Community Restoration, and the State Council on Developmental Disabilities. [GOV §12803 and §12806]
- Requires CHHSA or its departments, under the California Affordable Drug Manufacturing Act of 2020, to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs, as specified, and to increase patient access to affordable drugs. This program is referred to as CalRx. [HSC §127692(a)]
- Requires CalRx to enter into partnerships resulting in the production, procurement or distribution of generic drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Requires the generic drugs to be produced or distributed by a drug company or generic drug manufacturer that is registered with the U.S. Food and Drug Administration (FDA). Requires CalRx to only enter into partnerships to produce generic drugs at a price that results in savings, targets failures in the market for generic drugs, and improves patient access to affordable medications. [HSC §127693(a) and §127693(b)]
- Requires, in identifying generic prescription drugs to be produced, CHHSA to consider reports on prescription drug costs published by DMHC and the Department of Insurance (CDI), and pharmacy spending data from Medi-Cal and other entities for which the state pays the cost of generic prescription drugs. Requires the partnerships to include the production of at least one form of insulin, provided that a viable pathway for manufacturing a more affordable form of insulin exists. [HSC §127693(c)(1) and (2)]
- Authorizes CalRx, subject to appropriation, to enter into partnerships to increase competition, lower prices, and address supply shortages for: over-the-counter naloxone products; generic or brand name drugs to address emerging health concerns, including reproductive health care or gender affirming health care; development, production, procurement, or distribution of vaccines, as specified; and, the manufacture, purchase, or distribution of medical supplies or medication devices. [HSC §127697]
- Establishes the Public Employees’ Medical and Hospital Care Act and the Board of Administration of the Public Employees’ Retirement System (CalPERS) to provide health care, retirement, and other benefits to state and other government employees and retirees. [GOV §22750-§22755]
- Requires a health benefit plan or contract to provide coverage for an FDA-approved vaccine for AIDS, contraceptives and related services, and vasectomies and related services, consistent with laws that apply to health plans regulated by DMHC and insurers regulated by CDI. [GOV §22853.1, §22853.3, and 22853.4]
This bill:
- States intent to increase access to the California workforce, starting with state and local employees to identify, counsel, and treat chronic weight disease, and ensure treatments available through CalRx, including pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1 receptor agonist (GLP-1RA), glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP+GLP-1) tirzepatide, and future chronic weight disease products are available at the former Medi-Cal 2025 price, most favored nation price, or a better price.
- Requires, commencing January 1, 2027, a health benefit plan or contract that contracts with CalPERS to offer optional coverage for chronic weight disease management, including nutritional information and pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products, as part of one of its health plan options.
- Requires chronic weight disease management as described in 2) above to be offered at the cost previously provided to Medi-Cal beneficiaries in the year 2025, the most favored nation pricing, as set forth in a May 12, 2025, federal Executive Order, or better pricing.
- Requires chronic weight disease management as described above to follow FDA label indications for usage.
- Requires CHHSA to make chronic weight disease management medications described in 2) above to state and local government employers and determine if those medications should be made available to all Californians, as specified, at the cost described in 3) above.
- Sunsets 2) through 5) above on January 1, 2032.
- Requires CalRx to enter into partnerships resulting in the acquisition of brand name prescription drugs and requires CalRx to include the acquisition or production of pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP+GLP-1 tirzepatide, and future chronic weight disease products.
- Requires CalRx to consider the cost previously provided to Medi-Cal beneficiaries in the year 2025 or a lower cost, and the cost previously provided as the most favored nation pricing as set forth in a May 12, 2025, federal Executive Order, or better pricing.
- Requires any CalRx partnerships to consider guaranteeing access to supply of pens, vial injections, pills, and patches of GLP-1 semaglutide, GLP-1RA, GIP-GLP-1 tirzepatide, and future chronic weight disease products, and creating a state brand of those same products.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, chronic weight disease is a serious problem in the United States. There are approximately 24.5 million adults between the ages of 18-64 years living in California. According to UCLA’s California Health Interview Survey, nearly 61% of California adults fall into the combined overweight/obese category, which is associated with 200 morbid conditions, including 13 types of cancer. Chronic weight management can be related to reduced labor participation and earnings, increased early mortality, absenteeism, disability and healthcare costs exceeding $1 billion and a 2.6% reduction in the California Gross Domestic Product. CalPERS health insurance covers more than 1.5 million public employees. As the largest purchaser of public employee health benefits in California, the program provides coverage for over 1,200 public agencies and schools. This bill will require CalPERS to offer GLP-1s as an optional benefit through their health plan to reduce chronic weight management and reduce overall employer costs. Federal Executive Order authorized the Most-Favored-Nation Prescription Drug Pricing. This included offering GLP-1 medications at negotiated rate of $149 - $350 per month. These lower prices will be available through the Trump Rx platform. With CalRx offering affordable cost of $245 per month, 20% of California adults will reduce costs and employees will be more productive creating workforce savings.
- Most favored nation (MFN). In response to President Trump’s May 12, 2025 Executive Order, the federal Health and Human Services Department’s Center for Medicare and Medicaid Services (CMS) announced that the Secretary expects each drug manufacturer to commit to aligning U.S. pricing for all brand products across all markets that do not currently have generic or biosimilar competition with the lowest price of a set of economic peer countries. Specifically, the target price is the lowest price in an Organization for Economic Cooperation and Development country with a Gross Domestic Product per capita of at least 60% of the U.S. GDP per capita.
- Trump Rx. The TrumpRx.gov website indicates that it lists discounted drug prices from manufacturers that have agreed to MFN pricing. The site indicates that Americans can use the site to purchase drugs in cash, outside of their insurance, and these drugs can be obtained at participating pharmacies using coupon cards displayed on the site or directly through manufacturers’ websites. However, the site also says that it does not sell or dispense drugs, and that patients can access drugs through instructions shown for each individual drug offer. The site indicates commonly prescribed brand-name drugs are listed on the site, such as fertility and weight loss drugs. The site also indicates pharmacy payment will depend on how each manufacturer chooses to provide its discounted pricing. One of the GLP-1 drugs listed on the site indicates that it is available only to patients with commercial insurance or who are paying cash, but not patients enrolled in Medicare, Medicaid, or other government programs. The offer details indicate that the product is available at $149 each month until August 31, 2026, and then the price increases to $199 per month. The offer is subject to change or discontinuation without notice, is valid only at participating pharmacies (which are not listed), and cannot be combined with other offers or discounts. A telephone number and website of the manufacturer are listed for questions.
- Medicaid and Medicare. The Medicaid Drug Rebate Program provides a rebate to states for a portion of the Medicaid payment for each drug. The rebate is shared with the federal government. In return most manufacturer’s drugs are covered under state Medicaid programs. Some drugs or classes of drugs may be excluded from coverage, including drugs for weight loss. As of January 2026, 13 states covered GLP-1s for obesity treatment under Medicaid. Medicare beneficiaries in Part D prescription drug plans or Medicare Advantage plans may have coverage for GLP-1s for weight loss through CMS’ Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model beginning in January 2027 and short-term demonstration Medicare GLP-1 Bridge beginning July 2026. Participation in the BALANCE Model is optional for group retiree health plans. As of April 2026, CMS has defined a specified market wide enrollment threshold of 80% for implementation of the program. If that threshold is not obtained, the program will not be implemented.
- Medi-Cal Rx. Beginning in 2022, California consolidated pharmacy benefits under one system called Medi-Cal Rx, where the state pays for all drug claims on a fee-for-service basis, including for people in Medi-Cal managed care plans. Because of significant growth in the state’s pharmacy spending including for GLP-1 Agonists, in October 2025 pursuant to the enacted 2025-26 California state budget, Medi-Cal Rx announced that it will continue to cover GLP-1 medication when used for indications approved by the FDA, such as treating type 2 diabetes, atherosclerotic cardiovascular disease, and chronic kidney disease, subject to inclusion of a clinically appropriate International Classification of Diseases – 10 Revision diagnostic code, utilization controls, and medical necessity requirements. Three drugs for weight loss or weight-loss indications would no longer be covered effective January 1, 2026. Coverage would continue for certain FDA-approved indications and for people younger than 21 years of age pursuant to the federal Early and Periodic Screening, Diagnostic, and Treatment benefit. An analysis by the Legislative Analyst’s Office (LAO) points out that actual data on federal and state rebates are limited, mostly because drug-level-rebate information is confidential, which makes it difficult to assess Medi-Cal pharmacy spending. The Budget Act of 2025 included General Fund savings of $85 million, increasing to $680 million annually by 2028-29 from the elimination of Medi-Cal coverage of GLP-1 drugs.
- CalRx. HCAI’s Office of Health Care Affordability (OHCA) administers the CalRx program, which currently produces Insulin Glargine at $55 for a five-pack of 3mLpens and leverages the state’s purchasing power to buy naloxone at a reduced cost (twin pack of over-the-counter naloxone nasal spray for $19). CalRx also plans to launch a centralized ordering system to supply California schools with albuterol inhalers and single-use disposable spacers at no cost over a three-year period beginning this Summer. HCAI reported, through its 2023 CalRx Report to the Legislature, that it selected a nonprofit generic drug company, Civica Rx, as its partner to bring to market the three most popular insulin products (glargine, aspart, and lispro) under a CalRx branded label within the next two to three years. CalRx insulin prices are estimated to be about 90% lower than existing branded products, to save patients using insulin between $2,000 and $4,000 annually, and to provide much needed financial relief for people living with diabetes, especially those who are uninsured or underinsured and need insulin to maintain their health and quality of life. The report concluded that the entry of CalRx products into the drug market will likely increase price competition and help shift the industry from obscure, rebate-pricing towards more transparent, low pricing. Additionally, the report indicated it will be important for Civica to distribute CalRx insulin through both the existing supply chain as well as alternative distribution methods, such as sales channels that reach consumers more directly. In a 2025 CalRx Report to the Legislature, HCAI identified several challenges for the state in manufacturing generic drugs such as the high capital requirements, need for technical expertise, navigating complex regulatory requirements, dependency on vendors, contending with established global pharmaceutical companies, and decreased flexibility due to the need to commit funds to specific manufacturing capabilities. The report recommended that CalRx continue partnering with existing manufacturers on white label solutions (a drug manufacturer manufacturing products under the CalRx label) or focused investments. At an April 9, 2026, Senate Budget Health and Human Services Subcommittee hearing HCAI’s director indicated that GLP-1 antiobesity medications are among the drugs CalRx is considering for future inclusion.
- California Health Benefits Review Program (CHBRP) report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996 and reviewed this bill. CHBRP assumes this bill will require the CalPERS Premium Preferred Provider Organization (PPO) to cover the medications described in this bill (it is the only plan offered statewide) and that it will obtain the MFN pricing. CHBRP also indicates that there is no mechanism by which it will be possible to obtain MFN pricing so if MFN pricing is not obtained the estimated premium impacts will be higher. Key findings specific to the CalPERS requirements include:
- Overweight vs. Obese. Adults with body mass index (BMI) between 25 to 30 are categorized as overweight and those with a BMI of 30 or higher are categorized as obese. Total medical expenditures attributed to obesity in California are equal to $7.1 billion in 2025. This includes direct costs of public and private health expenditures and out-of-pocket costs. CHBRP estimates that 22.8% of CalPERS Basic non-Medicare enrollees (approximately 280,000) have obesity and 5.5% of CalPERS Basic non-Medicare enrollees (approximately 67,000) have BMIs between 27 and 30 with a weight-related comorbidity).
- GLP-1s. Currently, there are four GLP-1 medications approved for chronic weight management, and they are all available as subcutaneous injections with varying recommendations of frequency of administration. Oral formulations are likely to be available in the near future.
- Barriers. Rates of obesity vary by race and ethnicity, with Black (37.1%), Latino (39.4%), and American Indian/Alaska Native adults (45.6%) adults having higher rates compared to White (24.8%) and Asian (11.1%) adults. CHBRP cites studies that show people with obesity face stigma that makes them less likely to engage in the health care system. Many have financial barriers or are less likely to be prescribed treatment, and people in rural areas may have difficulties finding a provider who specializes in obesity treatment.
- Coverage impacts and enrollees covered. In 2027, approximately 1.2 million Californians would obtain health insurance through CalPERS. CHBRP estimates enrollment in a plan that newly includes coverage for GLP-1s would increase from 15.3% at baseline to 24% (approximately 10,000 CalPERS enrollees would switch into the PPO plan). CHBRP indicates one CalPERS HMO carrier voluntarily began offering a GLP-1 for weight management beginning in 2026, however there is no requirement for this to continue in 2027, and the HMO’s geographic coverage is geographically limited. CHBRP assumed a unit cost of $550 for the GLP-1s covered by this existing CalPERS HMO, and CHBRP estimated 187,000 CalPERS are in this plan. CHBRP also assumes that there are no impacts for Medicare beneficiaries in this analysis.
- Medical effectiveness. There is very strong evidence that FDA-approved GLP-1 medications for chronic weight management are effective when used as adjuncts to usual care (which includes standard diet and activity and lifestyle recommendations) for adults. Use of these medications increases the amount of weight loss and percentage of body weight loss, and reduces BMI, compared to placebo or usual care alone. There is strong evidence that GLP-1s improve weight loss in children and adolescents. There is very strong evidence that, for adults, gastrointestinal adverse events such as nausea, vomiting, indigestion, loss of appetite, headaches, abdominal pain, constipation, and diarrhea were more commonly experienced by GLP-1 groups than control groups. One medication was also associated with higher rates of gallbladder-related and pancreatic adverse events. For children and adolescents, there is very strong evidence that gastrointestinal events such as nausea, vomiting, and diarrhea are common while serious events are rare.
- Utilization. 17,335 enrollees will use coverage for GLP-1s with this bill (which includes 4,912 who already had coverage). The 17,335 includes 9,237 enrollees who currently self-pay, and 3,186 who would start because of new coverage in this bill. CHBRP applied a 20% annual discontinuance rate of GLP-1 medications, which reflects an average of discontinuation over several years. It is estimated that this bill would increase utilization of obesity treatment by 3,187 people per year. Assuming an average weight loss of 11.3%, this would translate into an approximate decrease in lost productivity of 2,679 days per year or $324,000 to $649,000 per year. These savings would grow over time.
- Impact on expenditures. CHBRP assumed MFN pricing of $245 per month, and self-pay pricing of $274 per month. Total premiums paid by employers and employees will increase by $330 per member or $35 million (a 26% increase) in the PPO plan annually because of this bill, this includes $52.31 annual premium increase for enrollees. This increase will apply to all enrollees in this PPO plan, including those who are not using GLP-1s. CHBRP projects cost offsets of $454 annually per GLP-1 user due to improved health status and reductions in other health care utilization. Total annual cost-sharing would increase by almost $3 million (9,237+3,186 x $240). Those who previously self-paid (9,237) would save $30 million (9,237x$274x12) or $3,048 ($3,288-240) annually. Their cost-sharing for GLP-1s through the PPO plan would be $240 per year ($20 per month).
- Public health. Enrollees newly using GLP-1s would experience an average of 4.8% to 17.8% reduction in body weight and improvements in related health improvements over time.
- Long-Term Impacts. Over time, utilization of GLP-1s among CalPERS enrollees would be expected to increase and therefore premium impacts would increase in the long term. Cost offsets from reduced obesity-related medical expenditures (cardiovascular events diabetes management, kidney disease, joint replacement) are expected to grow over time as enrollees maintain therapy. Competition from new entrants, biosimilars, and evolving pricing of GLP-1s may also affect long-term unit costs.
- Other states. As of March 2025, 16 states covered GLP-1 medications for weight loss under their state employee health plan. At least four states have terminated coverage due to the high costs associated with use of GLP-1 medications.
- Double referral. This bill is double referred. Should this bill pass out of this committee, it will be referred to the Committee on Labor, Public Employment & Retirement.
- Prior legislation. SB 535 (Richardson of 2025) would have required health plans and health insurers that provide coverage for outpatient prescription drug benefits to include coverage for intensive behavioral therapy, bariatric surgery, and at least one FDA-approved anti-obesity medication. SB 535 was held on the Assembly Appropriations Suspense File.
AB 575 (Arambula of 2025) was similar to SB 535. AB 575 was never heard in the Assembly Health Committee.
SB 1008 (Bradford of 2024) was substantially similar to SB 535. SB 1008 was held in the Senate Appropriations Committee.
SB 839 (Bradford of 2023) was substantially similar to AB 575, except that SB 839 did not prohibit prior authorization and prohibited cost-sharing from being different or separate from other illnesses, conditions, or disorders. SB 839 was not heard in the Senate Health Committee.
AB 116 (Committee on Budget, Chapter 21, Statutes of 2025) expands authority for CalRx to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns including reproductive health care, gender affirming health care, vaccines, medical supplies, and medical devices.
AB 118 (Assembly Committee on Budget, Chapter 42, Statutes of 2023) clarifies and provides additional flexibility for CalRx to procure various pharmaceutical drugs in addition to its existing efforts to manufacture generic forms of insulin.
SB 184 (Committee on Budget and Fiscal Review, Chapter 47, Statutes of 2022) permits, until December 31, 2027, CHHSA and its departments to enter into contracts on a bid or negotiated basis and exempts these contracts from review or approval by the Department of General Services for purposes of implementing CalRx.
SB 154 (Skinner, Chapter 43, Statutes of 2022), known as the Budget Act of 2022, appropriated $100 million to support the development of three low-cost biosimilar insulin products and a California-based insulin manufacturing facility, and required expenditures for construction or acquisition of the facility to result in full or partial ownership of the facility by the state.
SB 838 (Pan, Chapter 603, Statutes of 2022) requires CalRx to enter into a partnership to manufacture at least one form of insulin, to be made available at production and dispensing costs; requires this partnership to include representation and involvement with the governance of the contractor entity; and, requires CalRx, upon appropriation by the Legislature, to develop a California-based manufacturing facility for generic drugs, as specified.
SB 852 (Pan, Chapter 207, Statutes of 2020) establishes CalRx.
- Support. The American Diabetes Association (ADA) writes that GLP-1 and GLP-1RA medications have proven transformative in the management of type 2 diabetes and obesity, improving blood glucose control, reducing cardiovascular risk, and contributing to meaningful weight reduction, yet access to these medications remains severely limited for many Californians due to inconsistent insurance coverage. The ADA supports efforts that bring evidence-based, life-saving diabetes therapies within reach of all who need them—particularly those in low-income and working-class populations who face the greatest barriers to consistent care. The ADA indicates this bill aligns with their mission to prevent type 2 diabetes and to improve the lives of all people affected by it. California Primary Care Association (CPCA) Advocates write this bill is particularly important for community health centers and their patients. CPCA Advocates indicates the high cost of these drugs has placed them out of reach for many patients who are uninsured or underinsured. They write that this bill will help community health clinics provide more effective, evidence-based care.
- Policy comment. This bill requires CalRx to acquire brand name drugs as additional CalRx responsibilities. However, the authority for CalRx to enter into partnerships for brand name drugs to address emerging health concerns was provided last year through AB 116, subject to appropriation. This bill also specifically requires inclusion of a list of a variety of GLP-1 products and future chronic weight disease products in CalRx and requires any partnership to consider guaranteeing priority access for these products for the state to the same extent as insulin. Based on the two CalRx reports to the Legislature, the program is trying to balance the many objectives that the Legislature has charged them with since its inception. It is unclear where this group of drugs fits under its current charge, and if there are resources to pay for the acquisition of this class of costly drugs.
- Amendments. The Chair is requesting amendments to authorize CalRx to include at least one GLP-1 antiobesity medication rather than requiring inclusion of all the current GLP-1 antiobesity medications and future medications. Additionally, the CalPERS mandate should be limited to at least one GLP-1 antiobesity medication.
SUPPORT AND OPPOSITION:
Support: American Diabetes Association
California Academy of Family Physicians
California Orthopedic Association
California Primary Care Association
One individual
Oppose: None received
-- END --
Discussed in Hearing
Assembly Floor
Assembly Standing Committee on Health
Senate Floor
Senate Standing Committee on Labor, Public Employment and Retirement
Senate Standing Committee on Health
Bill Author
Bill Co-Author(s):